[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 66 of about 66
1. Mizuta Y, Akazawa Y, Shiozawa K, Ohara H, Ohba K, Ohnita K, Isomoto H, Takeshima F, Omagari K, Tanaka K, Yasutake T, Nakagoe T, Shirono K, Kohno S: Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas. Pancreatology; 2005;5(4-5):470-4
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas.
  • This case is unique due to the concurrent presence of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • Abdominal computed tomography revealed massive ascites, thickened peritoneum, and a cystic lesion of the pancreas.
  • No primary tumour, including mucinous neoplasm of the appendix, was found.
  • The patient received intraperitoneal perfusion of saline heated to 42 degrees C containing cisplatin, etoposide, and mitomycin C, followed by 24 courses of postoperative chemotherapy with gemcitabine.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / pathology. Chemotherapy, Cancer, Regional Perfusion. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Humans. Hyperthermia, Induced. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15983445.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 19
  •  go-up   go-down


2. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA: Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg; 2007 Jan;245(1):104-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
  • OBJECTIVE: To evaluate the survival of patients with pseudomyxoma peritonei (PMP) treated by cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC), and to identify factors with prognostic value.
  • SUMMARY BACKGROUND DATA: PMP is a clinical syndrome characterized by progressive intraperitoneal accumulation of mucous and mucinous implants, usually derived from a ruptured mucinous neoplasm of the appendix.
  • Survival was calculated from date of initial treatment and corrected for a second procedure.
  • Recurrence developed in 44%.
  • A second procedure for recurrence was performed in 11 patients.
  • The median disease-free interval was 25.6 months (95% confidence interval [CI], 14.8-43.6 months).
  • The 3-year and 5-year disease-free survival probability was 43.6% (95% CI, 34.4%-55.2%) and 37.4% (95% CI, 28.2%-49.5%), respectively.
  • The disease-specific 3-year and 5-year survival probability was 70.9% (95% CI, 62.0%-81.2%) and 59.5% (95% CI 48.7%-72.5%), respectively.
  • Factors associated with survival were pathological subtype, completeness of cytoreduction, and degree and location of tumor load (P < 0.05).
  • CONCLUSION: Cytoreductive surgery in combination with intraoperative HIPEC is a feasible treatment strategy for PMP in terms of survival.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Parenteral. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2005 Mar;20(2):155-60 [15503065.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):100-4 [16302177.001]
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):186-90 [16303281.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):393-8 [15070599.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(4):411-4 [15285293.001]
  • [Cites] Gastroenterology. 1986 Jan;90(1):202-5 [2998918.001]
  • [Cites] J Urol. 1988 Apr;139(4):821-2 [3352057.001]
  • [Cites] Can J Surg. 1989 May;32(3):164-70 [2713770.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):109-11 [8129480.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • [Cites] Obstet Gynecol. 1994 Jul;84(1):17-21 [8008316.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Hum Pathol. 1995 May;26(5):509-24 [7750935.001]
  • [Cites] Eur J Surg. 1995 May;161(5):355-60 [7662781.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1332-9 [9782010.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] J Surg Oncol. 2004 Feb;85(2):61-7 [14755505.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] J Surg Oncol. 2000 Dec;75(4):270-4 [11135270.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):54-8 [11237493.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • [Cites] Cancer Treat Rev. 2001 Dec;27(6):365-74 [11908929.001]
  • [Cites] Gastroenterol Clin Biol. 2003 Apr;27(4):407-12 [12759682.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [CommentIn] Ann Surg. 2008 Mar;247(3):556-7 [18376211.001]
  • (PMID = 17197972.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1867935
  •  go-up   go-down


3. Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, Ohinata A, Liu J, Wang X, Eng C: Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer; 2010 Jan 15;116(2):316-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience.
  • BACKGROUND: Appendiceal neoplasms include tumors ranging from benign-appearing cells with widespread mucin deposits to aggressive poorly differentiated signet ring cell adenocarcinomas.
  • Traditionally, these tumors are treated with cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy.
  • A retrospective analysis was conducted to determine the benefit of modern systemic chemotherapy in patients with disseminated appendiceal neoplasm who were not considered optimal candidates for cytoreductive surgery.
  • Anderson Cancer Center tumor registry between January 2000 and July 2005.
  • RESULTS: Of 186 patients diagnosed with appendiceal neoplasm, 54 (29%) patients considered to be suboptimal surgical candidates received > or =2 cycles of systemic chemotherapy.
  • Thirty (55.6%) patients had a disease control rate noted as a complete response, partial response, or stable disease.
  • CONCLUSIONS: Systemic chemotherapy has a role in appendiceal neoplasm patients who are suboptimal candidates for cytoreductive surgery.
  • The intermediate PFS indicates the challenges that exist for appendiceal neoplasm patients in this setting.
  • Prospective randomized trials including systemic chemotherapy are needed to provide further insight into this malignancy, for which no standard exists.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Appendiceal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Hyperthermia, Induced. Injections, Intraperitoneal. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19904805.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Gilboa Y, Fridman E, Ofir K, Achiron R: Carcinoid tumor of the appendix: ultrasound findings in early pregnancy. Ultrasound Obstet Gynecol; 2008 May;31(5):576-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumor of the appendix: ultrasound findings in early pregnancy.
  • Ultrasound examination of a woman in early pregnancy with right lower quadrant abdominal pain demonstrated an edematous appendix with amorphous fluid surrounding the appendix.
  • On pathological evaluation following surgical removal of the appendix a rare case of carcinoid tumor of the appendix was diagnosed.
  • This is the first description of the transvaginal ultrasound features of a carcinoid tumor of the appendix.
  • [MeSH-major] Appendiceal Neoplasms / ultrasonography. Carcinoid Tumor / ultrasonography. Pregnancy Complications, Neoplastic / ultrasonography
  • [MeSH-minor] Abdominal Pain / etiology. Abortion, Spontaneous / drug therapy. Adult. Female. Humans. Pregnancy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 ISUOG
  • (PMID = 18393270.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Elias D, Honoré C, Ciuchendéa R, Billard V, Raynard B, Lo Dico R, Dromain C, Duvillard P, Goéré D: Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg; 2008 Sep;95(9):1164-71
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is characterized by progressive intraperitoneal accumulation of mucous and mucinous implants, usually derived from a ruptured, possibly malignant mucinous neoplasm of the appendix.
  • Treatment based on complete cytoreductive surgery (CCRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is gaining support.
  • Overall and disease-free 5-year survival rates were 80.0 and 68.5 per cent respectively.
  • The Cox model identified only two significant factors impacting on disease-free survival: CA19.9 level and pathological grade.
  • CONCLUSION: CCRS is the most effective treatment for PMP, and adding HIPEC prolongs long-term survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Combined Modality Therapy / methods. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Hyperthermia, Induced. Injections, Intraperitoneal. Male. Organoplatinum Compounds / administration & dosage. Preoperative Care / methods. Prognosis. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18690633.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Topkan E, Polat Y, Karaoglu A: Primary mucinous adenocarcinoma of appendix treated with chemotherapy and radiotherapy: a case report. Tumori; 2008 Jul-Aug;94(4):596-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma of appendix treated with chemotherapy and radiotherapy: a case report.
  • A rare case of primary appendiceal mucinous adenocarcinoma is reported.
  • An appendectomy was performed resulting in a histological diagnosis of grade 2 mucinous adenocarcinoma of the appendix.
  • Two of the 17 resected lymph nodes were tumor positive but there was no residual tumor in the hemicolectomy specimen.
  • The patient was staged as T4N1M0 and adjuvant multimodality treatment was planned because he was considered at high risk for local-regional recurrence and distant metastasis.
  • Three cycles of capecitabine 1250 mg/m2 on days 1-14 and oxaliplatin 130 mg/m2 on day 1, every 21 days (CAPOX) were administered, then a total dose of 50.4 Gy external-beam radiation therapy was delivered to the primary tumor region and 45 Gy to the lymphatics, and finally 3 further cycles of the CAPOX regimen were administered.
  • Multimodality treatment was well tolerated by the patient, who is still alive 25 months after the hemicolectomy procedure with no evidence of disease progression.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / drug therapy. Appendiceal Neoplasms / radiotherapy. Colectomy
  • [MeSH-minor] Capecitabine. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Radiotherapy, Adjuvant. Treatment Outcome

  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18822701.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA: A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res; 2009 Oct 1;15(19):6137-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To develop a targeted biological drug that when systemically injected can penetrate to metastatic breast cancer tumors, one needs a drug of high potency and reduced immunogenicity.
  • Our purpose was to reduce toxin immunogenicity using mutagenesis, measure the ability of mutated drug to elicit B-cell antitoxin antibody responses, and show that mutated drug was effective against systemic breast cancer in vivo.
  • Finally, a genetically altered luciferase xenograft model was used; this model could be imaged in real time to determine the effect on the systemic malignant human breast cancer MDA-MB-231.
  • CONCLUSIONS: Because EGF4KDEL 7mut was highly effective even when we waited 26 days to begin therapy and because immunogenicity was significantly reduced, we can now give multiple drug treatments for chemotherapy-refractory breast cancer in clinical trials.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Med. 2000 Mar;6(3):165-78 [10965493.001]
  • [Cites] J Neurooncol. 2009 Dec;95(3):331-42 [19517064.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1593-611 [11920518.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1826-36 [12738741.001]
  • [Cites] In Vitro. 1974 Jan-Feb;9(4):239-45 [4471183.001]
  • [Cites] Int J Cancer. 1978 Feb 15;21(2):166-70 [203546.001]
  • [Cites] Cell. 1987 Mar 13;48(5):899-907 [3545499.001]
  • [Cites] J Cancer Res Clin Oncol. 1988;114(4):385-93 [3045130.001]
  • [Cites] Nature. 1989 Jun 1;339(6223):394-7 [2498664.001]
  • [Cites] Clin Exp Immunol. 1994 Jan;95(1):148-55 [8287600.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6889-93 [8041715.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):968-75 [9500458.001]
  • [Cites] Leuk Res. 2005 Mar;29(3):331-41 [15661270.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3879-88 [15897589.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6719-29 [16061911.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8822-34 [17142785.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3058-67 [17505009.001]
  • [Cites] Cancer Control. 2007 Jul;14(3):295-304 [17615536.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6486-93 [17975161.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5):1031-7; discussion 1037-8 [18091279.001]
  • [Cites] Gut. 2008 May;57(5):634-41 [18222985.001]
  • [Cites] Curr Protoc Immunol. 2001 May;Appendix 1:Appendix 1C [18432639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6 [18678888.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1440-8 [19065664.001]
  • [Cites] Leuk Res. 2009 Sep;33(9):1233-42 [19327829.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):258-66 [11801567.001]
  • (PMID = 19789305.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA036725-24; United States / NCI NIH HHS / CA / R01 CA108637; United States / NCI NIH HHS / CA / R01 CA082154; United States / NCI NIH HHS / CA / R01 CA108637-04; United States / NCI NIH HHS / CA / R01 CA036725; United States / NCI NIH HHS / CA / R01-CA36725; United States / NCI NIH HHS / CA / R01-CA082154; United States / NCI NIH HHS / CA / CA036725-24; United States / NCI NIH HHS / CA / R01 CA108637-03; United States / NCI NIH HHS / CA / CA108637-04; United States / NCI NIH HHS / CA / CA108637-03; United States / NCI NIH HHS / CA / R01 CA036725-23; United States / NCI NIH HHS / CA / CA036725-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunotoxins; 0 / Receptors, Interleukin-4; 0 / Recombinant Fusion Proteins; 62229-50-9 / Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS127356; NLM/ PMC2756320
  •  go-up   go-down


8. Pretto G, Grando M, Chella N Jr, Bergold RA, de Castro RA, Santiago A: Anesthesia for peritonectomy with hyperthermic intraoperative peritoneal chemotherapy. Case report. Rev Bras Anestesiol; 2010 Sep-Oct;60(5):551-7
MedlinePlus Health Information. consumer health - Anesthesia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anesthesia for peritonectomy with hyperthermic intraoperative peritoneal chemotherapy. Case report.
  • BACKGROUND AND OBJECTIVES: Pseudomyxoma peritonei is a rare condition related to epithelial neoplasia of the appendix and ovaries.
  • Surgical cytoreduction, peritonectomy, and hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the treatment of choice.
  • She was extubated on the 1(st) postoperative day, being discharged from the hospital on the 17(th) day of hospitalization.
  • Due to the complexity of the procedure and large surgery the vigilance of the anesthesiologist is fundamental for maintenance of clinical and laboratorial parameters, and recognition and treatment of any changes.
  • [MeSH-major] Anesthesia. Hyperthermia, Induced. Intraoperative Care. Peritoneal Neoplasms / therapy. Peritoneum / surgery. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Editora Ltda. All rights reserved.
  • (PMID = 20863936.001).
  • [ISSN] 1806-907X
  • [Journal-full-title] Revista brasileira de anestesiologia
  • [ISO-abbreviation] Rev Bras Anestesiol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


9. Innis M, Sandiford N, Shenoy RK, Prussia PR, Zbar A: Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy. West Indian Med J; 2005 Sep;54(4):242-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy.
  • Jejunal adenocarcinoma is rare, often presenting late with widespread intraperitoneal disease.
  • Intraperitoneal chemotherapy (IPC) has been shown in non-randomized studies to improve the survival of patients presenting with intraperitoneal metastases from carcinoma of the colon, appendix and stomach and in primary peritoneal malignancies including mesothelioma and pseudomyxoma peritonei, providing that adequate operative cytoreduction can be performed.
  • The patient was treated successfully with immediate postoperative IPC followed by systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16312191.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Jamaica
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Sugarbaker PH, Bijelic L, Chang D, Yoo D: Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol; 2010 Nov 1;102(6):576-81
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin.
  • BACKGROUND: A treatment option for patients with peritoneal mucinous carcinomatosis (PMCA) from an appendiceal neoplasm is cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • Also, these patients are recommended for systemic chemotherapy using an oxaliplatin and 5-fluorouracil (FOLFOX) regimen.
  • A major question concerns the proper timing (neoadjuvant vs. adjuvant) of the systemic chemotherapy.
  • METHODS: In January of 2005 a prospective study was initiated to routinely treat patients with peritoneal dissemination of a mucinous adenocarcinoma of the appendix with neoadjuvant chemotherapy using FOLFOX.
  • All patients had a clinical, CT, intraoperative, and histopathological assessment of chemotherapy effects.
  • In the clinical evaluation and CT evaluation, 24 (71%) and 22 (65%), respectively, had stable disease on chemotherapy.
  • CONCLUSIONS: In these carcinomatosis patients clinical and CT assessment of response to neoadjuvant chemotherapy seldom provided useful data over this short time period.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Humans. Injections, Intraperitoneal. Leucovorin / therapeutic use. Male. Middle Aged. Neoadjuvant Therapy. Organoplatinum Compounds / therapeutic use

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20737420.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


11. Kayikçioglu F, Köse MF, Boran N, Calişkan E, Tulunay G: Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer; 2001 Nov-Dec;11(6):466-70
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma.
  • Neoadjuvant chemotherapy has been proposed as an alternative approach to conventional surgery as initial management of bulky ovarian cancer, with the goal of performing adequate debulking in the interval surgery.
  • Neoadjuvant chemotherapy followed by interval surgery was performed in 45 of 205 patients.
  • The remaining 158 patients received primary surgery plus adjuvant chemotherapy.
  • In multivariate analysis, only residual tumor diameter and appendix involvement were found to affect total survival significantly in both groups.
  • Five-year survival and median survival were not statistically different when all patients treated conventionally were compared with all patients treated with neoadjuvant chemotherapy.
  • Primary chemotherapy followed by interval debulking surgery in a selected group of patients does not appear to worsen prognosis, but it permits less aggressive surgery and improves patients' quality of life.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / therapy. Aged. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / therapy. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies. Splenectomy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11906550.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Garin L, Corbinais S, Boucher E, Blanchot J, Le Guilcher P, Raoul JL: Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. Dig Dis Sci; 2002 Dec;47(12):2760-2
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
  • All pathology specimens exhibited an adenocarcinomatous component associated with carcinoid proliferation related to an appendicular tumor leading to the diagnosis of appendicular adenocarcinoid with ovarian, peritoneal, and nodal metastases.
  • Chemotherapy (Folfox 4 regimen) was given, and the patient improved within six weeks.
  • Presently, more than three years after the end of the treatment, the patient is still alive and in complete remission.
  • These tumors exhibit two cellular components.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / drug therapy. Fluorouracil / therapeutic use. Leucovorin / therapeutic use
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds. Ovarian Neoplasms / secondary

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Dec;42(6):2781-93 [728874.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):848-52 [7634979.001]
  • [Cites] J Surg Oncol. 1997 Sep;66(1):51-3 [9290693.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):75-80 [9510314.001]
  • [Cites] Surgery. 1992 Mar;111(3):244-50 [1542852.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • (PMID = 12498298.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


13. Stewart JH 4th, Shen P, Russell GB, Bradley RF, Hundley JC, Loggie BL, Geisinger KR, Levine EA: Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol; 2006 May;13(5):624-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy.
  • BACKGROUND: Appendiceal neoplasms frequently present with peritoneal dissemination (PD) and have a clinical course marked by bowel obstruction and subsequent death.
  • Few data have correlated outcome with appendiceal histology after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IPHC).
  • We have reviewed our experience with cytoreductive surgery and IPHC for PD from the appendix.
  • METHODS: A total of 110 cases of PD from proven appendiceal neoplasms treated with IPHC were identified from a prospectively managed database.
  • Tumor samples were classified on pathologic review as disseminated peritoneal adenomucinosis (n = 55), peritoneal mucinous carcinomatosis (PMCA) with intermediate features (n = 18), PMCA (n = 29), or high-grade nonmucinous lesions (n = 8).
  • RESULTS: A total of 116 IPHCs were performed on 110 patients for appendiceal PD between 1993 and 2004.
  • When stratified by histology, disseminated peritoneal adenomucinosis and intermediate tumors had better 3-year survival rates (77% +/- 7% and 81% +/- 10%) than PMCA and high-grade nonmucinous lesions (35% +/- 10% and 15% +/- 14%; P = .0032 for test of differences between groups).
  • Age at presentation (P = .0134), performance status (P < .0001), time between diagnosis and IPHC (P = .0011), resection status (P = .0044), and length of hyperthermic chemoperfusion (P = .0193) were independently associated with survival.
  • CONCLUSIONS: The data show that long-term survival is anticipated in most patients who are treated with cytoreduction and IPHC for appendiceal PD.
  • In all, this work establishes a framework for the consideration of IPHC in future trials for appendiceal PD.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Combined Modality Therapy. Disease Progression. Female. Humans. Hyperthermia, Induced. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2006 May;13(5):597-9 [16538404.001]
  • (PMID = 16538401.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA131482
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Nakamura S, Kimura S, Kashima M, Shichijo K, Yoshida S, Harada E, Matsushita T, Oshima Y, Tamaki Y, Horiuchi N, Takeichi T, Fujimoto H, Masuda K, Iwasaka N, Shinomiya S: [A case of peritonitis carcinomatosa from goblet cell carcinoid of the appendix treated by intraperitoneal paclitaxel and systemic S-1 chemotherapy]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2425-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of peritonitis carcinomatosa from goblet cell carcinoid of the appendix treated by intraperitoneal paclitaxel and systemic S-1 chemotherapy].
  • Goblet cell carcinoid of the appendix is a rare neoplasm and clinically tends to take a malignant course.
  • But appropriate chemotherapy for inoperable cases with peritoneal dissemination is not established.
  • Abdominal computed tomography showed massive ascites and slight contrast enhancement of appendix.
  • A tumor was found by colonoscopic examination at the orifice of vermiform and was diagnosed pathologically as goblet cell carcinoid of the appendix.
  • We performed intraperitoneal paclitaxel(PTX)administration at 70 mg/m(2) week without any resection of the tumor.
  • Ascites were reduced immediately, but drug-induced interstitial pneumonia occurred due to PTX.
  • After steroid therapy, we switched to systemic S-1 therapy.
  • For about one year, her tumor was controlled but became worse thirteen months after diagnosis and died.
  • It is thought that intraabdominal paclitaxel administration and systemic S-1 therapy can be one of appropriate forms of chemotherapy for inoperable peritoneal carcinomatosis from goblet cell carcinoid of appendix.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / drug therapy. Carcinoid Tumor / pathology. Oxonic Acid / therapeutic use. Paclitaxel / therapeutic use. Peritonitis / drug therapy. Peritonitis / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Colonic Neoplasms / complications. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colonoscopy. Drug Combinations. Female. Humans. Injections, Intraperitoneal. Tomography, X-Ray Computed. Treatment Failure

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098416.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Bijelic L, Yan TD, Sugarbaker PH: Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol; 2008 Sep 15;98(4):295-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms.
  • BACKGROUND: Peritonectomy combined with perioperative intraperitoneal chemotherapy is a successful treatment option for patients with peritoneal dissemination of appendiceal and colorectal malignancy.
  • METHODS: Patients with peritoneal dissemination from appendiceal or colorectal malignancy who underwent complete cytoreduction and perioperative intraperitoneal chemotherapy were included in this study.
  • Data regarding recurrent disease found on abdominal exploration and/or diagnostic studies was extracted from a prospective database and analyzed.
  • RESULTS: Seventy patients with colorectal cancer carcinomatosis and 402 with appendiceal neoplasm were analyzed.
  • Forty-nine of 70 and 111 of 402 patients developed documented recurrences.
  • The median survival of 49 patients with colorectal cancer was 33 months while the median survival for patients with appendiceal neoplasms was not reached.
  • The most common type of recurrent disease was a localized intra-abdominal recurrence for both appendiceal and colon cancer patients.
  • Patients who underwent second surgery for recurrent disease had an improved survival.
  • CONCLUSION: Additional treatments should be strongly considered in patients who fail an initial cytoreduction combined with perioperative intraperitoneal chemotherapy.
  • This resulted in 5-year survival in 17% of colorectal patients and 70% of the appendiceal mucinous neoplasm patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Appendiceal Neoplasms / pathology. Chemotherapy, Cancer, Regional Perfusion / methods. Colorectal Neoplasms / pathology. Hyperthermia, Induced. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cohort Studies. Female. Humans. Infusions, Parenteral. Male. Retrospective Studies. Survival Rate. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726900.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Moran BJ, Meade B, Murphy E: Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis of colorectal origin: a novel treatment strategy with promising results in selected patients. Colorectal Dis; 2006 Sep;8(7):544-50
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis of colorectal origin: a novel treatment strategy with promising results in selected patients.
  • Peritoneal carcinomatosis is a major cause of treatment failure in colorectal cancer with few options for treatment.
  • Recent reports, including a single randomized trial, suggest that localized peritoneal carcinomatosis, in the absence of other metastases, could be considered regional metastatic disease analogous to liver metastases, and thus amenable to locoregional therapy.
  • Optimal treatment involves complete tumour removal by complex surgical techniques, combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
  • This treatment strategy has significant morbidity and mortality risks and careful selection is essential to avoid futile procedures.
  • The best results are achieved in patients with limited disease who have complete macroscopic tumour removal, when the primary and peritoneal metastases are removed synchronously, and when the primary tumour is a cancer of the appendix.
  • Selected patients with localized disease have been shown to have good outcomes with prolonged survival and perhaps a possibility of cure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Colorectal Neoplasms / therapy. Hyperthermia, Induced. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Humans. Neoplasm, Residual

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919104.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 35
  •  go-up   go-down


17. Elias D, Glehen O, Pocard M, Quenet F, Goéré D, Arvieux C, Rat P, Gilly F, Association Française de Chirurgie: A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg; 2010 May;251(5):896-901

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix.
  • OBJECTIVE: To report a large number of patients with peritoneal carcinomatosis (PC) treated with complete cytoreductive (CCR-0) plus intraperitoneal chemotherapy, and to compare the results according to the origin of the primary: colon, rectum, small bowel, and appendix (excluding peritoneal pseudomyxoma).
  • PATIENTS AND METHODS: Among 615 patients treated for PC originating from these 4 types of primaries in 23 French centers, 440 were retrospectively selected as having undergone complete cytoreductive surgery and with complete data retrieval.
  • Primary sites were: colon (n=341), rectum (n=27), appendix (n=41), and small bowel (n=31).
  • RESULTS: Postoperative mortality and morbidity (3.9% and 31%, respectively) did not differ according to the origin of the primary tumor.
  • The 5-year overall survival rates were not statistically different for the colon (29.7%), rectum (37.9%), nor the small bowel (33.8%), but was higher (P=0.01) for appendix adenocarcinoma (63.2%).
  • The multivariate analysis of prognostic factors singled out the extent of peritoneal seeding (P<0.0001), positive lymph nodes (P=0.001), and adjuvant systemic chemotherapy (P=0.002), whereas the origin of the tumor was borderline (P=0.06) in favor of appendix tumors.
  • CONCLUSION: Cytoreductive surgery plus intraperitoneal chemotherapy yields satisfying and similar survival results in the treatment of PC from colon, rectum, and small bowel adenocarcinomas.
  • Results were better for appendix adenocarcinoma.
  • When feasible, this combined approach should become the gold standard treatment of PC.
  • [MeSH-major] Adenocarcinoma / secondary. Appendiceal Neoplasms / pathology. Colonic Neoplasms / pathology. Intestinal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Rectal Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans. Infusions, Parenteral. Liver Neoplasms / secondary. Multivariate Analysis. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395843.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Goere D, Elias D: [Appendiceal tumors found at appendectomy]. J Chir (Paris); 2009 Oct;146 Spec No 1:36-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Appendiceal tumors found at appendectomy].
  • [Transliterated title] Diagnostic de tumeur appendiculaire lors d'une appendicectomie.
  • There are three main histologic types of appendiceal tumor: adenoma, adenocarcinoma, and neuroendocrine tumor.
  • Neuroendocrine tumors (carcinoids) are by far the most common and account for two-third of all appendiceal tumors.
  • Rupture of any mucinous tumor-whether spontaneous or occurring during surgery-may result in pseudomyxoma peritonei; treatment of this condition requires complete resection of all lesions followed by hyperthermic intraperitoneal chemotherapy.
  • For unruptured appendiceal tumor, the appendix should be removed by a carcinologic right hemicolectomy if the tumor appears aggressive.
  • [MeSH-major] Appendectomy. Appendiceal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adenoma / diagnosis. Adenoma / surgery. Humans. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / surgery. Peritoneal Neoplasms / prevention & control. Pseudomyxoma Peritonei / prevention & control. Rupture / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846099.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 7
  •  go-up   go-down


19. Carmignani CP, Sugarbaker PH: Synchronous extraperitoneal and intraperitoneal dissemination of appendix cancer. Eur J Surg Oncol; 2004 Oct;30(8):864-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous extraperitoneal and intraperitoneal dissemination of appendix cancer.
  • BACKGROUND: The aim of this study was to report the role of combined treatments, including cytoreductive surgery and perioperative regional chemotherapy, in patients with synchronous systemic and intraperitoneal dissemination of appendix cancer.
  • METHODS: Patients with synchronous systemic and intraperitoneal dissemination of appendix cancer were treated with cytoreductive surgery and perioperative regional chemotherapy.
  • Variables statistically analyzed with survival as an end point included demographic characteristics, prior surgical score (PSS), tumour marker levels, peritoneal cancer index (PCI), and completeness of cytoreduction (CC).
  • RESULTS: Mean follow up was 42.6 months, median survival time (MST) for 15 patients was 28 months and 5-year survival rate was 29.4%.
  • CONCLUSION: Acceptable morbidity and mortality and a 29.4% 5-year survival rate allows cytoreductive surgery and regional chemotherapy to be considered as a treatment option for selected patients with synchronous systemic and intraperitoneal dissemination of appendix cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / pathology. Neoplasm Invasiveness / pathology. Neoplasms, Multiple Primary / therapy. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Combined Modality Therapy. Female. Humans. Infusions, Intralesional. Laparotomy / methods. Male. Middle Aged. Probability. Prognosis. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15336733.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Ouaïssi M, Julié C, Mitry E, Sielezneff I, Jimenez P, Loundou A, Benoist S, Penna C, Franc B, Rougier P, Nordlinger B: Prognostic factor of recurrence for resected digestive endocrine tumors. Hepatogastroenterology; 2009 Jul-Aug;56(93):1183-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factor of recurrence for resected digestive endocrine tumors.
  • Localization of tumours were as follows: 14 duodenopancreatic (DP) and 14 Digestive (DT: 9 small bowel and 4 appendix).
  • All resection of metastasis were performed during the same procedure of primary tumour resection.
  • There were 14 DT and 14 non functional DP tumours.
  • For 28 patients, the only factor of recurrence was endocrine pancreatic tumour (p = 0.02).
  • Survival free of disease for DT were: 100%,80% at 1, 5 yrs, and for DP they were 93%, 50%, 33% at 1, 3, 5 yrs, respectively.
  • CONCLUSION: The expression of the Ki67 antigen and differentiation seem to be good indicators for DP recurrence and may need an adjuvant treatment despite the R0 resection.
  • [MeSH-major] Endocrine Gland Neoplasms / surgery. Gastrointestinal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Predictive Value of Tests. Prognosis. Risk Factors. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760966.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


21. Swiatkowska-Freund M, Preis K, Emerich J: [Appendiceal mucinous carcinoma]. Ginekol Pol; 2000 Oct;71(10):1277-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Appendiceal mucinous carcinoma].
  • [Transliterated title] Rak śluzowy wyrostka robaczkowego.
  • Appendiceal carcinoma is very rare.
  • Preoperative diagnosis of this kind of neoplasm is difficult.
  • Even at operation in under half of cases this diagnosis is considered.
  • We present a case of a woman admitted to the hospital with diagnosis of adnexal tumor of the right ovary.
  • The diagnosis of adnexal mass was confirmed by ultrasound examination.
  • Laparotomy was performed and tumor of appendix was found.
  • There was also a small tumor (2 cm) in small bowel and some increased lymphatic nodules.
  • Uterus with adnexis, tumor of appendix, part of small bowel and colon were resected.
  • Because of infiltration of the neoplasm a part of the bladder was resected as well.
  • She received chemotherapy with 5-FU.
  • After 9 months computed tomography revealed no changes in abdomen.
  • Diagnosis of pelvic masses when they do not origin of adnexis is usually very difficult.
  • In many cases proper diagnosis is made only during laparotomy.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Intestinal Neoplasms / secondary. Intestinal Neoplasms / therapy. Laparotomy. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11143937.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Pahlavan PS, Kanthan R: Goblet cell carcinoid of the appendix. World J Surg Oncol; 2005 Jun 20;3:36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Goblet cell carcinoid of the appendix.
  • BACKGROUND: Goblet cell carcinoid (GCC) of the appendix is a rare neoplasm that share histological features of both adenocarcinoma and carcinoid tumor.
  • The clinical presentations of this neoplasm are also varied.
  • This review summarizes the published literature on GCC of the appendix.
  • The focus is on its diagnosis, histopathological aspects, clinical manifestations, and management.
  • METHODS: Published studies in the English language between 1966 to 2004 were identified through Medline keyword search utilizing terms "goblet cell carcinoid," "adenocarcinoid", "mucinous carcinoid" and "crypt cell carcinoma" of the appendix.
  • RESULTS: Based on the review of 57 published papers encompassing nearly 600 diagnosed patients, the mean age of presentation for GCC of the appendix was 58.89 years with equal representation in both males and females.
  • Accurate diagnosis of this neoplasm requires astute observations within an acutely inflamed appendix as this neoplasm has a prominent pattern of submucosal growth and usually lacks the formation of a well-defined tumor mass.
  • The most common surgical treatment of choice was appendectomy with right hemicolectomy in 34.70% followed by simple appendectomy in 24.57%.
  • Concomitant distant metastasis at diagnosis was present in 11.16% of patients with the ovaries being the most common site in 3.60% followed by disseminated abdominal carcinomatosis in 1.03%.
  • Local lymph node involvement was seen in 8.76% of patients at the time of diagnosis.
  • GCC's of the appendix remains a neoplasm of unpredictable biological behavior and thus warrants lifelong surveillance for recurrence of the disease upon diagnosis and successful surgical extirpation.
  • CONCLUSION: GCC of the appendix is a rare neoplasm.
  • Due to its wide range of presentation, this tumor should be considered as a possible diagnosis in many varied situations leading to abdominal surgery.
  • The advocated plan of management recommended for patients with tumors that involve the adjacent caecum or with high-grade tumors with histological features such as an increased mitotic rate involve initial appendectomy with completion right hemicolectomy due to the high possibility of local recurrence with intraperitoneal seeding prior to lymph node involvement and a 20% risk of metastatic behavior.
  • In female patients with GCC of the appendix regardless of age, bilateral salpingo-oophorectomy is advocated.
  • In cases with obvious spread of the disease chemotherapy, mostly with 5-FU and leucovorin is advised.
  • Cytoreductive surgery with adjuvant intraperitoneal chemotherapy can offer improved survival in cases with advanced peritoneal dissemination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Feb;30(2):112-5 [3803115.001]
  • [Cites] Cancer. 1974 Mar;33(3):770-7 [4815580.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Pathol Res Pract. 1984 Jul;178(6):555-61 [6483683.001]
  • [Cites] Gastroenterology. 1984 Feb;86(2):302-9 [6690357.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):286-8 [7076213.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Acta Obstet Gynecol Scand. 1982;61(2):153-6 [7113691.001]
  • [Cites] Diagn Gynecol Obstet. 1980 Winter;2(4):269-74 [7215111.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Cancer. 1978 Dec;42(6):2687-95 [728868.001]
  • [Cites] Cancer. 1978 Dec;42(6):2781-93 [728874.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(2):201-10 [7368563.001]
  • [Cites] Acta Morphol Acad Sci Hung. 1980;28(1-2):37-58 [7446221.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Diagn Cytopathol. 1995 Feb;12(1):59-61 [7789249.001]
  • [Cites] Intern Med. 1994 Jul;33(7):422-6 [7949643.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] J Clin Pathol. 1977 May;30(5):473-80 [864014.001]
  • [Cites] Histopathology. 1995 Dec;27(6):557-62 [8838336.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jan;15(1):85-8 [8852453.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):109-13 [8990147.001]
  • [Cites] Arch Pathol Lab Med. 1976 Jun;100(6):301-6 [946758.001]
  • [Cites] J Gastroenterol. 1998 Aug;33(4):582-7 [9719248.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Eur J Surg. 1999 Oct;165(10):993-7 [10574110.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):557-68 [11342766.001]
  • [Cites] Pathol Int. 2001 Apr;51(4):283-7 [11350611.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 Jul;97(1):90-5 [11435017.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):140-6 [11884049.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):551-64 [12163380.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2760-2 [12498298.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Surg Today. 2003;33(5):375-8 [12734735.001]
  • [Cites] Radiographics. 2003 May-Jun;23(3):645-62 [12740466.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1168-73 [15449269.001]
  • [Cites] Diagn Cytopathol. 1991;7(2):155-7 [1648469.001]
  • [Cites] Histopathology. 1991 Jan;18(1):61-5 [1672861.001]
  • [Cites] Leber Magen Darm. 1991 Sep;21(5):226,229-30 [1758238.001]
  • [Cites] Br J Urol. 1976 Dec;48(6):436 [188508.001]
  • [Cites] Acta Pathol Jpn. 1991 Jun;41(6):455-60 [1950561.001]
  • [Cites] Am J Clin Pathol. 1990 Jul;94(1):27-35 [2163192.001]
  • [Cites] Arch Pathol Lab Med. 1979 Apr;103(4):180-2 [218519.001]
  • [Cites] Gut. 1990 Mar;31(3):322-4 [2323597.001]
  • [Cites] Gut. 1990 Jul;31(7):840 [2370022.001]
  • [Cites] Int Surg. 1989 Apr-Jun;74(2):109-10 [2753618.001]
  • [Cites] J Surg Oncol. 1988 Jan;37(1):65-71 [2826924.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):930-3 [2994592.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;412(2):175-82 [3122418.001]
  • [Cites] Surg Gynecol Obstet. 1988 Jul;167(1):81-6 [3289135.001]
  • [Cites] Dis Colon Rectum. 1988 Aug;31(8):605-12 [3402286.001]
  • (PMID = 15967038.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1182398
  •  go-up   go-down


23. Yonemura Y, Tsukiyama G, Miyata R, Sako S, Endou Y, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Hagiwara A, Li Y: Indication of peritonectomy for peritoneal dissemination. Gan To Kagaku Ryoho; 2010 Nov;37(12):2306-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 521 patients with peritoneal carcinomatosis (PC) were treated by peritonectomy and perioperative chemotherapy.
  • Each of the 95, 58, 316, 31, 10 and 11 patients were from gastric, colorectal, appendiceal, ovarian, small bowel cancer and mesothelioma, respectively.
  • Peritonectomy was performed with a radical resection of the primary tumor and all gross PC with involved organs, peritoneum, or tissue that was deemed technically feasible and safe for the patient.
  • In appendiceal neoplasm, patients with PCI score less than 28 showed significantly better survival than those with PCI score greater than 29.
  • Among the various prognostic factors in appendiceal neoplasm and gastric cancer patients, CC-0 complete cytoreduction was the most important independent prognostic factor.
  • Peritonectomy is done to remove macroscopic disease and perioperative intraperitoneal chemotherapy to eradicate microscopic residual disease aiming to remove disease completely with a single procedure.
  • Peritonectomy combined with perioperative chemotherapy may achieve long-term survival in a selected group of patients with PC.
  • [MeSH-major] Carcinoma / surgery. Peritoneal Neoplasms / surgery. Peritoneum / surgery
  • [MeSH-minor] Aged. Appendiceal Neoplasms / drug therapy. Appendiceal Neoplasms / surgery. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / surgery. Male. Mesothelioma / drug therapy. Mesothelioma / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Postoperative Complications. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224556.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Tang LH, Shia J, Soslow RA, Dhall D, Wong WD, O'Reilly E, Qin J, Paty P, Weiser MR, Guillem J, Temple L, Sobin LH, Klimstra DS: Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol; 2008 Oct;32(10):1429-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix.
  • Appendiceal tumors exhibiting both neuroendocrine and glandular differentiation are uncommon and have caused difficulty in pathologic classification, prediction of prognosis, and clinical management.
  • In this study, we undertook a retrospective investigation of 63 such cases and classified them as typical GCC (group A) and adenocarcinoma ex GCC on the basis of the histologic features of the tumor at the primary site.
  • The adenocarcinoma ex GCC group was further divided into signet ring cell type (group B) and poorly differentiated adenocarcinoma type (group C).
  • The clinical characteristics and prognosis were compared within these groups and with conventional de novo appendiceal adenocarcinomas.
  • Both groups A and B tumors shared a similar immunoprofile, which included generally focal immunoreactivity for neuroendocrine markers, and a normal intestinal type mucin glycoprotein profile (negative MUC1 expression and preserved MUC2 immunoreactivity).
  • The proliferative index was relatively low in these tumors and slightly increased from groups A to B tumors (11% to 16%).
  • Both beta-catenin and E-cadherin exhibited a normal membranous staining pattern in groups A and B tumors.
  • The mean follow-up time was 49+/-5 (SE) months.
  • The overall disease-specific survival for all subtypes was 77%, with 46% of patients without evidence of disease and 31% alive with disease.
  • All the patients with clinical stage of I or IIA disease had a favorable outcome after appropriate surgery with or without chemotherapy.
  • Although most patients (63%) with GCC presented at an advanced clinical stage, their clinical outcome could be differentiated by subclassification of tumors.
  • In conclusion, GCC is a distinctive appendiceal neoplasm that exhibits unique pathologic features and clinical behavior.
  • They display a spectrum of histologic features and possess the potential to transform to an adenocarcinoma phenotype of either signet ring cell or poorly differentiated adenocarcinoma types.
  • [MeSH-major] Adenocarcinoma / pathology. Appendiceal Neoplasms / pathology. Carcinoid Tumor / pathology. Carcinoma, Signet Ring Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Appendectomy. Cell Differentiation. Cell Proliferation. Chemotherapy, Adjuvant. Colectomy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Observer Variation. Retrospective Studies. Terminology as Topic. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2009 Aug;33(8):1259-60; author reply 1260-1 [19471156.001]
  • (PMID = 18685490.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Sugarbaker PH: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol; 2006 Jan;7(1):69-76
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
  • Appendiceal mucinous neoplasms sometimes present with peritoneal dissemination, which was previously a lethal condition with a median survival of about 3 years.
  • Traditionally, surgical treatment consisted of debulking that was repeated until no further benefit could be achieved; systemic chemotherapy was sometimes used as a palliative option.
  • Now, visible disease tends to be removed through visceral resections and peritonectomy.
  • To avoid entrapment of tumour cells at operative sites and to destroy small residual mucinous tumour nodules, cytoreductive surgery is combined with intraperitoneal chemotherapy with mitomycin at 42 degrees C.
  • If the mucinous neoplasm is minimally invasive and cytoreduction complete, these treatments result in a 20-year survival of 70%.
  • In the absence of a phase III study, this new combined treatment should be regarded as the standard of care for epithelial appendiceal neoplasms and pseudomyxoma peritonei syndrome.
  • [MeSH-major] Appendiceal Neoplasms / drug therapy. Appendiceal Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Hyperthermia, Induced. Infusions, Parenteral. Mitomycin / administration & dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16389186.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Number-of-references] 38
  •  go-up   go-down


26. Järvinen P, Järvinen HJ, Lepistö A: Survival of patients with pseudomyxoma peritonei treated by serial debulking. Colorectal Dis; 2010 Sep;12(9):868-72
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PMP is a clinical condition characterized by disseminated intraperitoneal mucinous tumours often accompanied by mucinous ascites derived usually from an appendiceal neoplasm.
  • Patients with PMP have traditionally been treated by serial debulking, but aggressive cytoreduction followed by hyperthermic intraperitoneal chemotherapy is now advocated as standard treatment in PMP.
  • The patient characteristics and details of the treatment were analysed retrospectively.
  • However, four patients (12%) seemed to have achieved long-term disease-free survival of more than 5 years.
  • CONCLUSIONS: The 5-year survival is comparable with results achieved in patients receiving a combination of cytoreductive surgery and intraperitoneal chemotherapy, but in the long term, the latter seems superior.
  • [MeSH-major] Palliative Care / methods. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2010 Sep;12(9):872-3 [20718839.001]
  • (PMID = 19519686.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Velusamy A, Saw S, Gossage J, Bailey S, Schofield J: Combined adenocarcinoid and mucinous cystadenoma of the appendix: a case report. J Med Case Rep; 2009;3:28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined adenocarcinoid and mucinous cystadenoma of the appendix: a case report.
  • INTRODUCTION: Adenocarcinoid of the appendix is a rare malignant tumour with features of both adenocarcinoma and carcinoid, showing both epithelial and endocrine differentiation.
  • Mucinous cystadenoma is the commonest of the benign neoplasms of the appendix, with an incidence of 0.6% in appendicectomy specimens.
  • We report a rare combination of these tumours and discuss the latest treatment options.
  • Laparoscopy revealed an adenocarcinoid of the appendix in combination with mucinous cystadenoma.
  • CONCLUSION: Adenocarcinoids account for 2% of primary appendiceal malignancies.
  • Right hemicolectomy is generally advised if any of the following features are present: tumours greater than 2 cm, involvement of resection margins, greater than 2 mitoses/10 high-power fields on histology, extension of tumour beyond serosa.
  • Chemotherapy mostly with 5-Fluorouracil and Leucovorin is advised for remnant disease after surgery.
  • Cytoreductive surgery with intraperitoneal chemotherapy can offer improved survival for advanced peritoneal dissemination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2007 Nov-Dec;93(6):587-90 [18338494.001]
  • [Cites] Histopathology. 2007 Dec;51(6):763-73 [18042066.001]
  • [Cites] Endocr Pathol. 2007 Spring;18(1):16-22 [17652796.001]
  • [Cites] J Gastroenterol. 2006 Aug;41(8):745-9 [16988762.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):52-60 [16794389.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Histopathology. 1995 Dec;27(6):557-62 [8838336.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1436-9 [16136284.001]
  • (PMID = 19171048.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2647933
  •  go-up   go-down


28. González-Moreno S, Sugarbaker PH: Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg; 2004 Mar;91(3):304-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding.
  • BACKGROUND: Traditionally epithelial malignancies of the appendix with or without carcinomatosis have been treated by right hemicolectomy.
  • Recent accumulation of a large number of patients with this disease has enabled a re-evaluation of this surgical judgement.
  • METHODS: Clinical data on 501 patients with epithelial malignancy of the appendix were collected prospectively.
  • All patients had peritoneal seeding at the time of referral and were treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • The main independent variable for statistical analysis was the surgical procedure used to resect the primary cancer (appendicectomy alone versus right hemicolectomy).
  • RESULTS: Median follow-up after the initial diagnosis was 4 years.
  • When the incidence of lymph node metastasis was determined by histological type, it was statistically significantly higher in intestinal (66.7 per cent) than in mucinous (4.2 per cent) tumours (P < 0.001).
  • The surgical procedure (appendicectomy alone versus right hemicolectomy) had an influence on patient survival by univariate analysis (P < 0.001), but not by multivariate analysis (P = 0.258).
  • CONCLUSION: Right hemicolectomy does not confer a survival advantage in patients with mucinous appendiceal tumours with peritoneal seeding.
  • These data suggest that right hemicolectomy should be avoided unless metastatic involvement of the appendiceal or distal ileocolic lymph nodes is documented by biopsy, or the resection margin is inadequate.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / surgery. Colectomy / methods. Neoplasm Seeding. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Analysis of Variance. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 British Journal of Surgery Society Ltd.
  • (PMID = 14991630.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Lyman MD, Neuhauser TS: Precursor T-cell acute lymphoblastic leukemia/lymphoma involving the uterine cervix, myometrium, endometrium, and appendix. Ann Diagn Pathol; 2002 Apr;6(2):125-8
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor T-cell acute lymphoblastic leukemia/lymphoma involving the uterine cervix, myometrium, endometrium, and appendix.
  • This report presents a case of precursor T-cell acute lymphoblastic leukemia/lymphoma (ALL) involving the uterine cervix, myometrium, endometrium, and appendix.
  • The patient was a 38-year-old woman with a history of ALL who had been in remission for 4 years following chemotherapy.
  • The patient was again treated with chemotherapy but her disease did not respond.
  • She succumbed to her disease approximately 10 months after her initial evaluation for symptoms related to ALL relapse.
  • This case shows some of the varied manifestations of precursor T-cell ALL and highlights the necessity of considering the female reproductive tract as a possible location of relapsing disease.
  • [MeSH-major] Appendix / pathology. Leukemic Infiltration / pathology. Precancerous Conditions / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Uterus / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Fatal Outcome. Female. Humans. Hysterectomy. Immunohistochemistry. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004362.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


30. Maier M, Kettelhack Ch, Adams H, Bongartz G, Sonnet S: [Presentation of right lower quadrant pain with atypical findings]. Praxis (Bern 1994); 2006 May 31;95(22):907-11
MedlinePlus Health Information. consumer health - Appendicitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Rechtsseitige Unterbauch- schmerzen mit atypischem Befund.
  • Laparoscopy showed a ruptured appendiceal mucocele with peritoneal adherent mucus.
  • The patient was treated with ileocecal resection.
  • Histopathological examination revealed an infiltrating mucinous cystadenocarcinoma of the appendix.
  • The patient will be treated with adjuvant intraperitoneal chemotherapy.
  • Despite typical clinical signs of appendicitis a sonographically atypical cystic mass in the right lower abdomen should raise suspicion of a mucocele, eventually on the base of a neoplasm.
  • [MeSH-major] Abdominal Pain / etiology. Appendiceal Neoplasms / ultrasonography. Appendicitis / ultrasonography. Cecal Diseases / ultrasonography. Cystadenocarcinoma / ultrasonography. Mucocele / ultrasonography
  • [MeSH-minor] Appendix / pathology. Appendix / surgery. Cecum / pathology. Cecum / surgery. Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm Staging. Rupture, Spontaneous

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16774049.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Piolat C, Courtot H, Plantaz D, Nugues F, Durand C, Jacquier C, Pasquier D, Dyon JF: [Surgical aspects of intussusception due to lymphoma in children]. Arch Pediatr; 2004 Jan;11(1):40-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Aspects chirurgicaux des invaginations intestinales sur lymphome chez l'enfant.
  • All patients underwent laparotomy: biopsy of massive abdominal tumor 6 and 8 weeks following resection of an intussusception (two cases), ileal resection of non-reductible intussusception (one case), right hemicolectomy for tumor of the appendix (one case), tumorectomy of localized ileal tumor (two cases), enlarged mesenteric lymph node biopsy associated with simple reduction of intussusception (one case).
  • All children were successfully treated with protocol chemotherapy with a 15-month to 13-year follow-up.
  • Diagnosis of lymphoma may be difficult after manual reduction of intussusception.
  • Intestinal resection allows to reduce the intensity of chemotherapy but must be as limited as possible: ileal resection in cases of complicated intussusception, tumorectomy "in sano" in cases of ileal parietal isolated tumor.
  • Reduction of intussusception alone (with no resection of ileal tumor) seems to be effective if diagnosis of lymphoma is possible from peripheral samples (peritoneal fluid, pleural effusion, mesenteric lymph node, bone marrow biopsy...).
  • [MeSH-major] Ileal Neoplasms / complications. Intussusception / etiology. Intussusception / surgery. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14700760.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


32. Esquivel J, Sugarbaker PH: Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg; 2001 Aug;234(2):198-205
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients.
  • OBJECTIVE: To establish selection criteria for reoperation in patients with peritoneal dissemination from appendiceal malignancy.
  • SUMMARY BACKGROUND DATA: The outcome of patients with mucinous appendiceal neoplasms with peritoneal surface dissemination has changed as a result of a better understanding of the clinical and pathologic features of this disease.
  • This knowledge, combined with aggressive strategies for the use of perioperative intraperitoneal chemotherapy and peritonectomy procedures, has resulted in long-term disease-free survival in many of these patients.
  • However, some of the patients develop progressive disease, and a question regarding additional surgery is appropriate.
  • A critical analysis of the results of second-look surgery should assist in the management of patients with recurrent peritoneal surface dissemination of an appendiceal neoplasm.
  • METHODS: Three hundred twenty-one patients with epithelial peritoneal surface malignancy of appendiceal origin underwent surgery during a 12-year period.
  • Ninety-eight of these patients (30.5%) underwent a second-look procedure.
  • All patients were managed by a treatment regimen that used cytoreductive surgery and intraperitoneal chemotherapy.
  • Patients who had second-look surgery with bowel obstruction as a symptom and those in whom the amount of tumor was increased or minimally decreased at the first and second cytoreductions had a significantly inferior 5-year survival rate.
  • CONCLUSIONS: Follow-up of patients treated for peritoneal dissemination from neoplasms of appendiceal origin is indicated.
  • Selected patients in whom recurrence develops are candidates for repeat cytoreductive surgery plus intraperitoneal chemotherapy with curative intent.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / surgery. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Drug Administration Schedule. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Mitomycin / administration & dosage. Reoperation. Survival Rate

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] J Am Coll Surg. 1995 Dec;181(6):530-8 [7582228.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):413-9 [10448292.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • [Cites] World J Surg. 1999 Jan;23(1):23-9 [9841759.001]
  • [Cites] G Chir. 1999 Mar;20(3):81-6 [10217864.001]
  • [Cites] Cancer Treat Res. 1996;82:79-100 [8849945.001]
  • (PMID = 11505065.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1422006
  •  go-up   go-down


33. Umer MA, Date RS, Mellor S, Nair B, Ward JB: Hodgkin's disease of appendix: report of a case. Colorectal Dis; 2009 Nov;11(9):985-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease of appendix: report of a case.
  • BACKGROUND: A number of cases of non Hodgkin's lymphoma of the appendix have been described, but Hodgkin's lymphoma is extremely rare.
  • METHOD: We report a case of a 65-year-old gentleman who was treated for suspected Crohn's disease.
  • He failed to respond to medical treatment and underwent right haemicolectomy.
  • The resected segment of bowel demonstrated classical Hodgkin's disease originating in the appendix.
  • He recovered well from the operation and responded well to postoperative chemotherapy.
  • CONCLUSION: Hodgkin's lymphoma of appendix is extremely rare.
  • This case demonstrates the significance of repeated clinical evaluation of patients particularly in the absence of expected response to therapy.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Neoplasm Staging. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175635.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


34. Lanuke K, Mack LA, Temple WJ: Phase II study of regional treatment for peritoneal carcinomatosis. Am J Surg; 2009 May;197(5):614-8; discussion 618
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of regional treatment for peritoneal carcinomatosis.
  • BACKGROUND: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy is becoming an accepted treatment of carcinomatosis.
  • METHODS: Between February 2000 and January 2008, there were 101 consecutive patients with carcinomatosis who were treated with cytoreductive surgery + hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy.
  • Patient and tumor characteristics, surgical details, complications, disease-free survival (DFS), and overall survival (OS) were recorded prospectively.
  • RESULTS: The majority (82%) of patients, median age 49 years (range, 18-77 y), had complete macroscopic cytoreduction (completeness of cytoreduction score, 0) despite a generally extensive tumor burden.
  • Preliminary median DFS and OS have not been defined for appendix tumors at a median follow-up period of 16 months (range, 1-86 mo).
  • Median DFS and OS for colonic tumors are 8 months and 26 months, respectively, with a median follow-up period of 12 months (range, 1-48 mo).
  • CONCLUSIONS: Combined regional treatment is feasible and holds significant promise for the treatment of peritoneal carcinomatosis.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Appendiceal Neoplasms / pathology. Chemotherapy, Cancer, Regional Perfusion. Colorectal Neoplasms / pathology. Disease-Free Survival. Female. Humans. Hyperthermia, Induced. Male. Middle Aged. Mitomycin / administration & dosage. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19393354.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


35. Omohwo C, Nieroda CA, Studeman KD, Thieme H, Kostuik P, Ross AS, Holter DR, Gushchin V, Merriman B, Sardi A: Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology. J Am Coll Surg; 2009 Sep;209(3):308-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.
  • BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a rapidly evolving treatment for metastatic appendiceal neoplasms.
  • The aim of this study was to show the effect of complete cytoreduction (CC) on survival in patients undergoing CRS and HIPEC for high-grade appendiceal neoplasm.
  • STUDY DESIGN: A retrospective study of a prospective database of 56 patients (from 1999 to 2007) with appendiceal neoplasms treated with CRS and HIPEC was carried out.
  • Histology of the disease, CC score, and peritoneal cancer index (PCI) score were assessed independently and collectively for each group of patients.
  • Survival analysis by tumor histology was 80% for patients with low-grade tumors and 52% for patients with high-grade tumors (p = 0.024).
  • There was no statistically significant difference in survival between the low-grade and high-grade tumors when a complete cytoreduction was performed in both groups of patients: 80% versus 68% (p = 0.69).
  • CONCLUSIONS: CRS and HIPEC is an effective treatment for patients with disseminated appendiceal tumors.
  • High-grade tumors also benefit from this approach and should not be excluded from CRS and HIPEC.
  • Every effort should be made to achieve a complete cytoreduction regardless of the tumor histology.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Appendiceal Neoplasms / pathology. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Chi-Square Distribution. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Reoperation. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717034.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  •  go-up   go-down


36. Sugarbaker PH, Bijelic L: The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Tumori; 2008 Sep-Oct;94(5):694-700
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • BACKGROUND: A successful new treatment for a particular disease may change the natural history of that disease as patients go on to longer survival.
  • The goal of this study was to investigate the porta hepatis as a site of recurrence of appendiceal mucinous neoplasms.
  • METHODS: A prospective database on patients with peritoneal dissemination of mucinous appendiceal neoplasms has been maintained for 21 years.
  • In patients with complete cytoreduction, disease progression/recurrence in and around the porta hepatis has been noted as a new manifestation of this disease.
  • RESULTS: In 710 patients treated for mucinous appendiceal cancer with a complete cytoreduction, 140 developed recurrent disease.
  • Seven patients (5%) had disease recurrence in and around the porta hepatis.
  • CONCLUSIONS: Progression of mucinous neoplasms within the porta hepatis may be related to imperfect cytoreduction technique.
  • Reoperative surgical treatment and biliary stents were beneficial in some of these patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendectomy. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Appendicitis / surgery. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Perioperative Care. Prospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112943.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Bolanowski M, Jarzab B, Handkiewicz-Junak D, Jeziorski A, Kos-Kudła B, Zajecki W, oraz Pozostali Uczestnicy Konferencji Okragłego Stołu: [Neuroendocrine tumors of the small intestine and the appendix - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)]. Endokrynol Pol; 2008 Jan-Feb;59(1):87-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine tumors of the small intestine and the appendix - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)].
  • [Transliterated title] Guzy neuroendokrynne jelita cienkiego i wyrostka robaczkowego ( zasady postepowania rekomendowane przez Polska Siec Guzow Neuroendokrynnych).
  • Polish recommendations regarding management of patients suffering from neuroendocrine tumors of small intestine and appendix are presented.
  • Small intestine, especially ileum represent most common origin of these tumors.
  • Symptoms are atypical, diagnosis could be often accidental.
  • Chromogranin A is useful in the laboratory diagnostics, and urinary excretion of 5-hydroxyindoloacetic acid is helpful for the diagnostics and monitoring of the disease.
  • Ultrasound, colonoscopy, capsule endoscopy, baloon enteroscopy, computed tomography, magnetic resonance and somatostatin analogs scintigraphy could be used for the visualization.
  • The treatment of choice in the neuroendocrine tumors of small intestine and appendix is radical or palliative surgery, if possible using endoscopy.
  • Pharmacotherapy consists of biotherapy and chemotherapy.
  • The crucial in biotherapy is somatostatin analogs application, possible in symptomatic treatment of hormonally functioning tumors.
  • This is treatment of choice in carcinoid crisis.
  • Chemotherapy is less successful in disseminated or locally advanced intestinal neuroendocrine tumors, so radioisotope therapy should be considered in each case of unresectable tumor.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy. Practice Guidelines as Topic
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / therapy. Clinical Competence. Combined Modality Therapy / methods. Endoscopy, Gastrointestinal / methods. Humans. Intestine, Small. Neoplasm Staging. Physical Examination. Poland. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18335403.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Investigator] Bar-Andziak E; Cwikła J; de Herder W; Dzielicki J; Falconi M; Foltyn W; Gaciong Z; Hubalewska-Dydejczyk A; Kowalska A; Krolicki L; Krzyzanowska-Swiniarska B; Kryszałowicz B; Kvols L; Nasierowska-Guttmejer A; O'Toole D; Kunikowska J; Lampe P; Matyja V; Mełen-Mucha G; Milewicz A; Nowak A; Nowakowska-Duława E; Omyła-Staszewska J; Pajak J; Rudzki S; Rydzewska G; Sowinski J; Starzynska T; Strzelczyk J; Sworczak K; Syrenicz A; Szawlowski A; Tomaszewska RA; Wasko-Czopnik D; Wronski M; Zemczak A; Zgliczynski W
  •  go-up   go-down


38. Toumpanakis C, Standish RA, Baishnab E, Winslet MC, Caplin ME: Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. Dis Colon Rectum; 2007 Mar;50(3):315-22
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Goblet cell carcinoid tumors (adenocarcinoid) of the appendix.
  • PURPOSE: Goblet cell appendiceal carcinoids represent rare tumors that exhibit histologic features of both adenocarcinomas and neuroendocrine tumors.
  • We present the long-term results of a series of 15 patients, focusing on clinical manifestations, diagnosis, and management.
  • Final diagnosis was confirmed by histology.
  • Right hemicolectomy was performed in all except one, who subsequently developed metastases.
  • Three patients had metastases at previous diagnosis.
  • Ki67 index was greater than 20 percent in all of them, while in only one with local tumor.
  • Combination chemotherapy with either cisplatin plus etoposide or with 5-fluorouracil, cisplatin, and streptozotocin was administered to all patients with metastases resulting in temporary stabilization of disease.
  • Twelve patients are alive, while three died of their disease 9, 13, and 14 months after diagnosis.
  • CONCLUSIONS: The diagnostic value of chromogranin-A, urinary 5-hydroxy-indol-acetic acid, and (111)Indium-labeled octreotide scintigraphy seems to be limited in these tumors.
  • Ki67 index appears to predict tumor behavior.
  • Chemotherapy may have efficacy in metastatic disease, however, more data are required to determine this and the optimal regimen.
  • [MeSH-major] Appendiceal Neoplasms / diagnosis. Carcinoid Tumor / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendectomy. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Colectomy. Combined Modality Therapy. Diagnosis, Differential. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Streptozocin / administration & dosage

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195086.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 5W494URQ81 / Streptozocin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Roy P, Chetty R: Goblet cell carcinoid tumors of the appendix: An overview. World J Gastrointest Oncol; 2010 Jun 15;2(6):251-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Goblet cell carcinoid tumors of the appendix: An overview.
  • Goblet cell carcinoid is an enigmatic and rare tumor involving the appendix almost exclusively.
  • Since its identification in 1969, understanding of this disease has evolved greatly, but issues regarding its histogenesis, nomenclature and management are still conjectural.
  • Various other names have been used for this entity such as adenocarcinoid, mucinous carcinoid, crypt cell carcinoma, and mucin-producing neuroendocrine tumor, although none have been found to be completely satisfactory or universally accepted.
  • The tumor is thought to arise from pluripotent intestinal epithelial crypt-base stem cells by dual neuroendocrine and mucinous differentiation.
  • These may be of signet ring cell type or poorly differentiated adenocarcinoma.
  • Recently molecular studies have shown these tumors to lack the signatures of adenocarcinoma but they have some changes similar to that of ileal carcinoids (allelic loss of chromosome 11q, 16q and 18q).
  • The natural history of GCC is intermediate between carcinoids and adenocarcinomas of the appendix.
  • The most important prognostic factor is the stage of disease.
  • Appendectomy and right hemicolectomy are the main modalities of treatment, followed by adjuvant chemotherapy in select cases.
  • There is some debate about the surgical approach for these tumors, and a summary of published series and recommendations are provided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160637.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2998842
  • [Keywords] NOTNLM ; Appendiceal neoplasm / Goblet cell carcinoid / Mucin-producing neuroendocrine tumor of appendix
  •  go-up   go-down


40. Ahmed K, Hoque R, El-Tawil S, Khan MS, George ML: Adenocarcinoma of the appendix presenting as bilateral ureteric obstruction. World J Surg Oncol; 2008;6:23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the appendix presenting as bilateral ureteric obstruction.
  • BACKGROUND: Adenocarcinoma of the vermiform appendix is a rare neoplasm of the gastrointestinal tract.
  • These presentations reflect various stages of a locally expanding tumour causing luminal obstruction of appendix.
  • The patient was referred for chemotherapy where he received infusional 5 fluorouracil but died 7 months after surgery.
  • Every attempt should be made to make a precise diagnosis through all the available means to direct the treatment along correct lines.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Appendiceal Neoplasms / complications. Appendiceal Neoplasms / diagnosis. Ureteral Obstruction / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Arch Surg. 1977 May;112(5):666-7 [856108.001]
  • [Cites] J La State Med Soc. 1991 Nov;143(11):29-31 [1753179.001]
  • [Cites] Tumori. 1993 Dec 31;79(6):447-9 [8171749.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):154-70 [8000994.001]
  • [Cites] Surg Today. 2005;35(2):168-71 [15674503.001]
  • [Cites] Urology. 2004 May;63(5):981-2 [15135001.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):597-605 [12370661.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):695-8 [12370673.001]
  • [Cites] Korean J Gastroenterol. 2004 Jan;43(1):29-34 [14745249.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(1):113-5 [15053078.001]
  • [Cites] Rozhl Chir. 2005 Jan;84(1):33-6 [15813454.001]
  • (PMID = 18291037.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2277416
  •  go-up   go-down


41. Sugarbaker PH: Epithelial appendiceal neoplasms. Cancer J; 2009 May-Jun;15(3):225-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial appendiceal neoplasms.
  • The appendiceal malignancies usually arise within a mucocele.
  • The tumor within this structure can be minimally aggressive or of an invasive character.
  • If a low-grade appendiceal malignancy is removed intact, recurrence does not occur.
  • If rupture of the wall of the mucocele occurs with either low-grade or high-grade disease, the epithelial cells within will disseminate to the peritoneal surfaces.
  • If the diagnosis of peritoneal dissemination of an appendiceal malignancy has been established, a new treatment with curative intent is indicated.
  • Cytoreductive surgery is combined with perioperative intraperitoneal chemotherapy as a comprehensive management plan.
  • In approximately 900 patients treated at the Washington Cancer Institute, the quantitative prognostic indicators for appendiceal cancer with peritoneal dissemination have been determined.
  • Patients with a complete cytoreduction and low-grade tumor have an 80% survival at 20 years; with high-grade tumors, the survival drops to approximately 45%.
  • The extent of malignancy present within the abdomen by the peritoneal cancer index has a significant impact on survival for both high-grade and low-grade disease.
  • The most important indicator is the completeness of cytoreduction; for both high-grade and low-grade disease, all patients with an incomplete cytoreduction have died by 10 years.
  • These results of treatment can be achieved with a 19% incidence of severe complications and a 2% mortality.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556909.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


42. Murphy EM, Farquharson SM, Moran BJ: Management of an unexpected appendiceal neoplasm. Br J Surg; 2006 Jul;93(7):783-92
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for appendiceal neoplasm .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of an unexpected appendiceal neoplasm.
  • BACKGROUND: Appendiceal neoplasms are rare and most present unexpectedly as acute appendicitis.
  • METHODS: A systematic literature review was performed to access relevant publications on the presentation, pathology and management of appendiceal tumours.
  • RESULTS: Appendiceal tumours account for 0.4 to 1 per cent of all gastrointestinal tract malignancies and are found in 0.7 to 1.7 per cent of appendicectomy specimens.
  • Most are cured by simple appendicectomy if the tumour is less than 2 cm in size and does not involve the resection margin or mesoappendix.
  • Epithelial tumours may present with, or in time develop, pseudomyxoma peritonei, the optimal management of which involves complete tumour resection and intraperitoneal chemotherapy, usually available only in specialized centres.
  • CONCLUSION: Suggested algorithms for the management of unexpected appendiceal tumours are provided.
  • Recommendations are made for follow-up of patients with a perforated appendiceal epithelial tumour.
  • [MeSH-major] Appendectomy / methods. Appendiceal Neoplasms / surgery
  • [MeSH-minor] Humans. Incidental Findings. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 British Journal of Surgery Society Ltd.
  • (PMID = 16775823.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 94
  •  go-up   go-down


43. Toubai T, Kondo Y, Ogawa T, Imai A, Kobayashi N, Ogasawara M, Kiyama Y, Higa T, Sato K, Miyokawa N, Tanaka J, Imamura M, Kasai M: A case of leukemia of the appendix presenting as acute appendicitis. Acta Haematol; 2003;109(4):199-201
Hazardous Substances Data Bank. MERCAPTOPURINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of leukemia of the appendix presenting as acute appendicitis.
  • Macroscopically, the appendix was greatly swollen and reddened, but had no abscess.
  • He received induction chemotherapy, but died 49 days after admission.
  • Leukemic cell infiltration of the appendix is rare and acute appendicitis as the initial manifestation of leukemia is even rarer.
  • [MeSH-major] Appendicitis / etiology. Appendix / pathology. Cytarabine / analogs & derivatives. Leukemia, Myeloid, Acute / complications. Leukemic Infiltration / complications. Sarcoma, Myeloid / complications
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Aged. Antigens, CD / analysis. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendectomy. Combined Modality Therapy. Daunorubicin / administration & dosage. Disease Progression. Fatal Outcome. Humans. Idarubicin / administration & dosage. Immunophenotyping. Male

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Appendicitis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12853694.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 04079A1RDZ / Cytarabine; 9YVR68W306 / enocitabine; E7WED276I5 / 6-Mercaptopurine; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


44. Mandai M, Konishi I, Tsuruta Y, Suginami N, Kusakari T, Iwasaki T, Fujii S: Krukenberg tumor from an occult appendiceal adenocarcinoid: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol; 2001 Jul;97(1):90-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Krukenberg tumor from an occult appendiceal adenocarcinoid: a case report and review of the literature.
  • Appendiceal neoplasms with ovarian metastasis are rare.
  • A 35-year-old woman with a left ovarian tumor underwent left salpingo-oophorectomy, partial resection of the right ovary, and a total hysterectomy.
  • Pathological diagnosis of both ovaries was typical, Krukenberg tumor with signet-ring cells, and the second laparotomy revealed an occult appendiceal tumor to be the primary lesion.
  • The appendix showed no evidence of malignant change of the mucosa, but the tumor cells were observed infiltrating from the basiglandular region into the underlying stroma, associated with mucocele.
  • Although, argentaffin and argyrophil staining were negative, a few tumor cells showed immunohistochemical positivity for Chromogranin A.
  • Accordingly, the tumor was diagnosed as adenocarcinoid rather than adenocarcinoma of the appendix.
  • A review of the literature showed less than 40 cases of metastatic ovarian tumor from appendiceal primary, one-third of which were occult and could be detected at the second laparotomy.
  • Cisplatin-based chemotherapy may have partial effect in the treatment of patient with adenocarcinoid tumor.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Carcinoid Tumor / pathology. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromogranin A. Chromogranins / analysis. Cisplatin / therapeutic use. Fallopian Tubes / surgery. Fatal Outcome. Female. Humans. Hysterectomy. Immunohistochemistry. Intestinal Obstruction / etiology. Ovariectomy. Peritonitis / etiology

  • Genetic Alliance. consumer health - Adenocarcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11435017.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 27
  •  go-up   go-down


45. Piso P, Werner U, Bektas H, Kubicka S, Manns MP, Klempnauer J: [Peritoneal carcinosis in appendiceal carcinoma--at what price can the prognosis be improved?]. Dtsch Med Wochenschr; 2000 Oct 27;125(43):1283-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal carcinosis in appendiceal carcinoma--at what price can the prognosis be improved?].
  • BACKGROUND AND AIM: Many patients with appendix carcinoma develop peritoneal carcinomatosis with poor prognosis.
  • The purpose of this study was to look for results of multimodality treatment in these patients.
  • PATIENTS AND METHODS: Data of 13 patients (11 men, 2 women, median age 58 years) with proven peritoneal carcinomatosis from appendiceal carcinoma, operated between 07/1995 and 10/1998 were analysed retrospectively with special regard to extent of resection, postoperative morbidity and mortality, survival.
  • Intraoperatively, after resection, an open, hyperthermic intraperitoneal chemotherapy with Cisplatin was performed.
  • After a median follow-up of 36 months all patients survived the therapy (excepting two postoperative deaths).
  • CONCLUSIONS: In selected patients with advanced appendix carcinoma and peritoneal carcinomatosis prognosis can be improved by peritonectomy with intraperitoneal hyperthermic chemotherapy.
  • [MeSH-major] Adenocarcinoma / secondary. Appendiceal Neoplasms / surgery. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Peritoneum / pathology. Peritoneum / surgery. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11098226.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


46. Schrofer C, Villiger P, Cathomas R: [Multiple primary neoplasms - coincidence or tumor syndrom?]. Praxis (Bern 1994); 2009 Sep 9;98(18):1027-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple primary neoplasms - coincidence or tumor syndrom?].
  • BACKGROUND: Multiple primary neoplasms occur either by hazard or in the context of hereditary cancer syndromes, after chronic toxic exposition, in immunodeficiency or as secondary malignancies after radio- and/or chemotherapy.
  • CASE REPORT: We present the history of an actually asymptomatic female patient with four different malignancies within 30 years: malignant melanoma (1976), liposarcoma (1983), carcinoma of the appendix (2006) and lymphoma (2006).
  • DISCUSSION: There is not only a remarkable variety of malignant tumors but also an extraordinary long survival without recurrence of the generalised malignomas of the skin and soft tissue (malignant melanoma and liposarcoma).
  • It is difficult to explain the entire restitution with the implemented treatments (several tumor resections, chemotherapy with Ifosfamide).
  • More than 20 years after chemotherapy, the lymphoma can be classified as a secondary malignoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Ileal Neoplasms / diagnosis. Liposarcoma / diagnosis. Lymphoma, Follicular / diagnosis. Melanoma / diagnosis. Neoplasms, Second Primary / diagnosis. Skin Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Lymph Nodes / pathology. Neoplasm Staging. Syndrome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19739050.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


47. Greco L, Papa U: [Mucinous cystoadenocarcinoma of the appendix. A case report]. Ann Ital Chir; 2006 Jul-Aug;77(4):355-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous cystoadenocarcinoma of the appendix. A case report].
  • [Transliterated title] Il mucocele maligno dell'appendice vermiforme. Descrizione di un caso.
  • CASE REPORT: The Authors report a case of a 66-years-old male patient with mucinous cystoadenocarcinoma of the appendix.
  • Preoperative diagnosis was appendiceal mucocele.
  • At laparatomy was revealed the presence of a large mass of the appendix involving the caecum.
  • Hystology revealed diagnosis of mucinous cystoadenocarcinoma of the appendix.
  • After two weeks patient underwent right hemicolectomy, he is alive without disease at 36 months follow up.
  • Mucinous cystic neoplasms of the appendix is an uncommon disease that is rarely suspected before surgery.
  • CONCLUSIONS: The Authors stress the importance of an appropriate surgical treatment.
  • Right hemicolectomy appears to be the appropriate treatment with aggressive debulking when mucinous cystoadenocarcinoma is associated with pseudomyxoma peritonei.
  • The role of chemotherapy in the treatment of patients with appendiceal cancers remains controversial.
  • No controlled data on the efficacy of adjuvant chemotherapy are available.
  • All patients with any form of appendiceal tumor appear to have an increased incidence of synchronous and metachronous neoplasms, especially in the gastrointestinal tract, and should be investigated and followed up appropriately.
  • [MeSH-major] Appendiceal Neoplasms. Cystadenocarcinoma, Mucinous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139968.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


48. Bruin SC, Verwaal VJ, Vincent A, van't Veer LJ, van Velthuysen ML: A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin. Ann Surg Oncol; 2010 Sep;17(9):2330-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin.
  • OBJECTIVE: To predict clinical outcome by classification of peritoneal metastases (PM) of colorectal or appendiceal origin.
  • BACKGROUND: This study investigates whether standardized histological classification can predict outcome for PM of colorectal or appendiceal origin treated with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • For overall survival (OS) and disease-free survival (DFS) Cox proportional-hazard models were constructed.
  • Covariates included tumor, patient, and treatment characteristics.
  • RESULTS: PM could be categorized into four groups: low-grade, well-differentiated mucinous tumor (DPAM); intermediated-grade mucinous carcinoma (PMCA-i); high-grade mucinous carcinoma (PMCA); and high-grade nonmucinous carcinoma (PCA).
  • Multivariate analysis showed that histological classification, gender, number of segments affected, completeness of cytoreduction, and HIPEC as primary treatment were significant related to OS and DFS.
  • Of PM originating from an appendix tumor, 29% were of non-DPAM type.
  • Of primary colorectal tumors, 37% resulted in mucinous PM, and another 26% of PM of colorectal origin had partly mucinous histology.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / pathology. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232161.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Angelescu N, Bordea A, Popa E, Constantinescu N, Zodieru I, Mircea N: [Pseudomyxoma peritonei (gelatinous peritonitis )]. Chirurgia (Bucur); 2001 Sep-Oct;96(5):443-51
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical findings and biologic analysis were not specific and the imagistic explorers didn't permit the preoperative diagnosis.
  • The patients were submitted to variate surgical procedures, based on the benign (4 cases) or malignant (2 cases) character of the disease and on the origin of the lesions: cystadenoma of the appendix with secondary tumours of the ovary (the 2 females) and, respectively, cystadenoma and cytsadenocarcinoma of the appendix, mucinous paraenteric cyst with pseudomyxoma retroperitonei, mucinous recto-sigmoidian neoplasm (the 4 men).
  • We practiced intraperitoneal chemotherapy with Thio-Tepa in 5 cases (intraoperative in 4 cases) and systemic, with 5-FU and mytomicine, in one case.
  • The global 5-year survival rate was 60% (100% in the benign disease and 0% in the malignant form).
  • CONCLUSION: P.P. is a rare disease, still poorly understood.
  • The origin of the disease is the appendix (70-80%) and less frequently the ovary.
  • The treatment associates radical surgery and intraperitoneal chemohyperthermia, in specialised centres, but the prognosis still remains poor (50-70% 5-year global survival rate).
  • [MeSH-major] Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12731187.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 26
  •  go-up   go-down


50. Koren R, Dekel Y, Ramadan E, Veltman V, Dreznik Z: Periappendiceal actinomycosis mimicking malignancy report of a case. Pathol Res Pract; 2002;198(6):441-3
Hazardous Substances Data Bank. METRONIDAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of a periappendiceal actinomycosis, seen in an 83-year-old woman, clinically mimicking a right ovarian neoplasm penetrating the right colon, is presented.
  • We discuss a possible pathogenesis and the therapeutic modalities.
  • [MeSH-major] Actinomyces / isolation & purification. Actinomycosis / diagnosis. Appendix / pathology. Cecal Diseases / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Abscess / microbiology. Abscess / pathology. Aged. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Appendectomy. Cefotaxime / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Female. Humans. Metronidazole / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anaerobic Actinomyces Infection.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12166903.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 140QMO216E / Metronidazole; N2GI8B1GK7 / Cefotaxime
  •  go-up   go-down


51. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol; 2001 Sep;12(9):1295-300
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients.
  • In 1992 octreotide was introduced in the Netherlands as a palliative treatment for the carcinoid syndrome in metastatic carcinoid disease.
  • The aims of this epidemiological study were to evaluate epidemiological data and the impact of octreotide on survival in metastatic carcinoid disease.
  • PATIENTS AND METHODS: Between 1989 and 1996, 2391 patients with carcinoid disease were diagnosed in the Netherlands.
  • Under the age of 35 years, appendiceal carcinoid was the most frequently diagnosed primary site.
  • Incidence of distant metastases at diagnosis for appendix and lung primary sites was 1.6% and 5.5%, compared to 40%, in the other primary sites.
  • Multivariate analysis of 619 patients revealed that age, stage and appendix localisation predicted survival.
  • In metastatic disease, however, only year of diagnosis after 1992 independently predicted survival (P = 0.012).
  • Improved survival in metastatic carcinoid disease might relate to the use of octreotide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697843.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


52. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I: An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A; 2008 Aug 12;105(32):11311-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recombinant immunotoxins are hybrid proteins composed of an Fv that binds to a tumor antigen fused to a bacterial or plant toxin.
  • BL22 has produced many complete remissions in drug-resistant Hairy cell leukemia, where many treatment cycles can be given, because neutralizing antibodies do not form.
  • In marked contrast, only minor responses have been observed in trials with immunotoxins targeting solid tumors, because only a single treatment cycle can be given before antibodies develop.
  • To allow more treatment cycles and increase efficacy, we have produced a less immunogenic immunotoxin by identifying and eliminating most of the B cell epitopes on PE38.
  • The new immunotoxin (HA22-8X) is significantly less immunogenic in three strains of mice, yet retains full cytotoxic and anti-tumor activities.
  • Elimination of B-cell epitopes is a promising approach to the production of less immunogenic proteins for therapeutic purposes.

  • COS Scholar Universe. author profiles.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8616-20 [1924323.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8822-34 [17142785.001]
  • [Cites] Circulation. 1996 Jul 15;94(2):197-206 [8674179.001]
  • [Cites] J Protein Chem. 1996 Oct;15(7):691-700 [8968960.001]
  • [Cites] Nat Biotechnol. 1996 Oct;14(10):1239-45 [9631086.001]
  • [Cites] Trends Biotechnol. 1998 Dec;16(12):513-20 [9881483.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):148-55 [10077166.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3187-96 [15749848.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5696-704 [16110029.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5840-6 [16115924.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6719-29 [16061911.001]
  • [Cites] Dev Biol (Basel). 2005;122:171-94 [16375261.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):559-65 [16794638.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1622-36 [10764422.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1476-87 [10778980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8548-53 [10890891.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1425-32 [10942387.001]
  • [Cites] N Engl J Med. 2001 Jul 26;345(4):241-7 [11474661.001]
  • [Cites] Proteomics. 2002 Mar;2(3):271-9 [11921443.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):995-1002 [11948105.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3520-6 [12429643.001]
  • [Cites] Annu Rev Med. 2007;58:221-37 [17059365.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):430-4 [16421906.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] Curr Protoc Immunol. 2001 May;Appendix 1:Appendix 1C [18432639.001]
  • [Cites] Protein J. 2004 Jan;23(1):39-52 [15115181.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2402-10 [15162148.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):39058-67 [15150267.001]
  • [Cites] Biotechniques. 1990 May;8(5):528-35 [2357375.001]
  • [Cites] Pharmacotherapy. 2003 Aug;23(8 Pt 2):3S-8S [12921216.001]
  • [Cites] Methods Mol Biol. 2004;248:503-18 [14970517.001]
  • [Cites] Curr Opin Mol Ther. 2004 Feb;6(1):10-6 [15011776.001]
  • [Cites] Biochim Biophys Acta. 1994 May 27;1198(1):27-45 [8199194.001]
  • (PMID = 18678888.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Bacterial Toxins; 0 / Enterotoxins; 0 / Epitopes, B-Lymphocyte; 0 / Exotoxins; 0 / RFB4(dsFv)-PE38 recombinant immunotoxin; 0 / Recombinant Fusion Proteins; 0 / Virulence Factors; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / toxA protein, Pseudomonas aeruginosa
  • [Other-IDs] NLM/ PMC2516223
  •  go-up   go-down


53. Rassu PC, Cassinelli G, Ronzitti F, Bronzino P, Stanizzi T, Casaccia M: [Primary adenocarcinoma of the appendix. Case report and review of the literature]. Minerva Chir; 2002 Oct;57(5):695-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the appendix. Case report and review of the literature].
  • [Transliterated title] Adenocarcinoma primitivo dell'appendice. Descrizione di un caso clinico e revisione della letteratura.
  • A rare case of primary adenocarcinoma of the vermiform appendix (less than 250 cases described in the literature) in a 36 year-old female patient presenting signs and symptoms of an acute appendicitis is reported.
  • Adeno-carcinoma of the vermiform appendix is a rare neoplasm of the gastrointestinal tract with an incidence of about 0,01-0,2%.
  • Usually the diagnosis of adenocarcinoma of the vermiform appendix is difficult because symptoms and signs are not pathognomonic.
  • In the case described, the diagnosis was intra and postoperative and confirmed by the pathological examination of the surgical specimens.
  • At laparotomy, performed under suspicion of an acute appendicitis, disseminated disease was discovered, characterized by the involvement of the two ovaries, the left colon, the cecum, the vermiform appendix, with a peritoneal carcinosis and a hydroureteronephrosis.
  • According to the dissemination of the disease, the surgical treatment was right hemicolectomy, anterior resection of left colon, bilateral oophorectomy and omentectomy.
  • Adjuvant therapy was performed for 6 cycles, with 5FU and oxaliplatinum.
  • The patient is still alive after 6 months and there is no sign of progression of the disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Appendiceal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Appendectomy. Appendicitis / diagnosis. Cecal Neoplasms / drug therapy. Cecal Neoplasms / secondary. Cecal Neoplasms / surgery. Chemotherapy, Adjuvant. Colonic Neoplasms / drug therapy. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Hydronephrosis / etiology. Laparotomy. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12370673.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 13
  •  go-up   go-down


54. Beyrouti MI, Beyrouti R, Frikha F, Ben Amar M, Abid M, Ben Ameur H, Ben Salah K, Guirat A, Boujelben S: [Peritoneal gelatinous ascites]. Presse Med; 2007 Jul-Aug;36(7-8):1141-7
Genetic Alliance. consumer health - Gelatinous Ascites.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It most often follows a mucinous tumor of the appendix.
  • Preoperative diagnosis is facilitated by modern imaging techniques.
  • Ultrasonography and computed tomography provide complementary signs: septa and scalloping of the liver margins, respectively.
  • Effusion in the lesser peritoneal cavity suggests this diagnosis.
  • Magnetic resonance imaging, by showing the gelatinous ascites, their septa and the scalloping of liver and spleen, can strengthen the probability of the diagnosis.
  • Recurrence is more frequent in the forms associated with malignant or bipolar tumors.
  • Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the only therapy shown to be effective in cases of recurrence or malignant forms.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / diagnosis. Pseudomyxoma Peritonei / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Appendectomy. Biopsy, Needle. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hyperthermia, Induced. Laparotomy. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / therapy. Paracentesis. Preoperative Care. Rare Diseases. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603922.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


55. Ross A, Sardi A, Nieroda C, Merriman B, Gushchin V: Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC. Eur J Surg Oncol; 2010 Aug;36(8):772-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.
  • BACKGROUND: Appendiceal malignancies with peritoneal spread have been successfully treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • The aim of this study is to clarify the utility of common tumor markers in selecting patients for the combined treatment.
  • METHODS: Data on 56 patients with appendiceal neoplasms treated with CRS and HIPEC were prospectively collected.
  • Chi square test was used to analyze a link between common tumor markers and completeness of cytoreduction score (CC score) and preoperative peritoneal cancer index score (PCI score).
  • Hazard ratio of disease related death was 5.6 (95% CI, 1.8-17.2) among patients with high CC score as compared to those with low CC score.
  • Number of abnormal tumor markers (0 vs 1/2/3) correlated with PCI score 16.2 vs 32.5 (p < 0.001) but not with completeness of cytoreduction or survival.
  • CONCLUSIONS: Multiple abnormal tumor markers were not useful as an exclusion criterion for patients undergoing CRS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / immunology. Appendiceal Neoplasms / surgery. Biomarkers, Tumor / blood. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / immunology. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Chemotherapy, Adjuvant. Confounding Factors (Epidemiology). Female. Humans. Male. Middle Aged. Patient Selection. Predictive Value of Tests. Prospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20561764.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


56. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA, Committee of the National Cancer Research Institute: Guidelines for the welfare and use of animals in cancer research. Br J Cancer; 2010 May 25;102(11):1555-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focusing on animal welfare, we present recommendations on all aspects of cancer research, including: study design, statistics and pilot studies; choice of tumour models (e.g., genetically engineered, orthotopic and metastatic); therapy (including drugs and radiation); imaging (covering techniques, anaesthesia and restraint); humane endpoints (including tumour burden and site); and publication of best practice.
  • [MeSH-major] Animal Experimentation / standards. Animal Welfare / standards. Neoplasms / pathology. Neoplasms / therapy. Practice Guidelines as Topic
  • [MeSH-minor] Algorithms. Animals. Biomarkers, Pharmacological / analysis. Biomedical Research / ethics. Biomedical Research / legislation & jurisprudence. Biomedical Research / organization & administration. Biomedical Research / standards. Cell Line, Transformed. Diagnostic Imaging. Disease Models, Animal. Female. Humans. Male. Mice. Neoplasm Transplantation / methods. Neoplasm Transplantation / pathology. Neoplasm Transplantation / standards. Treatment Outcome. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Cancer. 2010 May 25;102(11):1553-4 [20502459.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):640-4 [9679770.001]
  • [Cites] Anal Chem. 2007 Nov 1;79(21):8312-5 [17910417.001]
  • [Cites] Drug Resist Updat. 2008 Feb-Apr;11(1-2):51-60 [18165147.001]
  • [Cites] Inhal Toxicol. 2003 Sep 15;15(11):1133-43 [12955618.001]
  • [Cites] Hepatology. 2006 Sep;44(3):602-11 [16941710.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Oct;19(10):1192-8 [15377299.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):304-10 [18240927.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 6;98(17):1176-8 [16954466.001]
  • [Cites] Curr Drug Metab. 2006 Feb;7(2):165-82 [16472106.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4429-40 [16547501.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):827-36 [15120038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(3):473-6 [1735681.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]
  • [Cites] Carcinogenesis. 2009 Dec;30(12):2100-8 [19808857.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):821-5 [14729596.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9 [16585152.001]
  • [Cites] Neuroimage. 2009 Apr 1;45(2):360-9 [19154791.001]
  • [Cites] Mol Imaging. 2004 Jul;3(3):149-58 [15530250.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8651-6 [15574773.001]
  • [Cites] Clin Diagn Lab Immunol. 2000 Mar;7(2):141-4 [10702484.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):305-11 [12527927.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):143-50 [19117997.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):580-9 [18385732.001]
  • [Cites] Methods Mol Med. 2005;111:323-34 [15911988.001]
  • [Cites] ILAR J. 2002;43(4):244-58 [12391400.001]
  • [Cites] ILAR J. 2002;43(2):100-9 [11917161.001]
  • [Cites] Haematologica. 2006 Feb;91(2):176-83 [16461301.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5624-31 [15313900.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6297-302 [11507085.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):294-7 [15549090.001]
  • [Cites] Comb Chem High Throughput Screen. 2010 Feb;13(2):170-87 [20053162.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16375-80 [19805307.001]
  • [Cites] Pediatr Res. 2005 Jan;57(1):67-75 [15557109.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] J Med Chem. 2006 Jun 29;49(13):3948-54 [16789751.001]
  • [Cites] J Appl Toxicol. 2001 Jan-Feb;21(1):15-23 [11180276.001]
  • [Cites] Curr Protoc Immunol. 2008 Aug;Chapter 20:Unit 20.9.1-20.9-10 [18729063.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):493-7 [11920607.001]
  • [Cites] J Neurooncol. 2005 May;73(1):29-36 [15933813.001]
  • [Cites] Stat Med. 2005 Jan 15;24(1):109-19 [15523707.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):821-6 [15120037.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4952-9 [12941820.001]
  • [Cites] Bioorg Med Chem. 2008 Jul 1;16(13):6611-6 [18502135.001]
  • [Cites] Oncogene. 2009 Nov 12;28(45):4009-21 [19718054.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3605-11 [10910075.001]
  • [Cites] Urol Res. 1991;19(4):207-13 [1926654.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2006 Mar-Apr;42(3-4):63-9 [16759150.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):645-58 [17687385.001]
  • [Cites] J Nutr. 2009 Dec;139(12):2373-9 [19864400.001]
  • [Cites] Cancer Immunol Immunother. 2004 Nov;53(11):946-54 [15185012.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):32-7 [18550454.001]
  • [Cites] J Immunol Methods. 1994 Jun 24;172(2):209-17 [7518484.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(16):2128-36 [12387838.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):428-40 [17308044.001]
  • [Cites] J Neurochem. 2008 Dec;107(5):1358-68 [19013850.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):241-6 [15936723.001]
  • [Cites] Curr Drug Metab. 2002 Oct;3(5):527-50 [12369896.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):59-64 [20029424.001]
  • [Cites] Exp Hematol. 2002 Jan;30(1):89-96 [11823042.001]
  • [Cites] Am J Bioeth. 2009 Dec;9(12):55-9 [20013503.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3827-34 [18483267.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):718-26 [15924142.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):621-81 [16968952.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Lab Anim. 2001 Jan;35(1):1-41 [11201285.001]
  • [Cites] Nat Med. 2001 Jul;7(7):864-8 [11433354.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):739-41 [16915261.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):843-8 [9615730.001]
  • [Cites] Peptides. 2007 Sep;28(9):1896-901 [17544169.001]
  • [Cites] Nature. 2008 Oct 2;455(7213):679-83 [18716624.001]
  • [Cites] J Pediatr Surg. 2007 Jul;42(7):1172-9 [17618876.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):741-54 [16915232.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2702-7 [8610104.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2168-77 [17404101.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1801-8 [10469627.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):83-6 [11544530.001]
  • [Cites] Dis Model Mech. 2010 Jan-Feb;3(1-2):111-9 [20007486.001]
  • [Cites] J Biomed Biotechnol. 2007;2007(3):97939 [17541473.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):809-15 [18253114.001]
  • [Cites] J Natl Cancer Inst. 1991 May 1;83(9):627-32 [1708835.001]
  • [Cites] Clin Pharmacol Ther. 2009 Feb;85(2):217-21 [19005462.001]
  • [Cites] FASEB J. 2009 Aug;23(8):2662-72 [19325038.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6537-41 [15374965.001]
  • [Cites] J Pharm Sci. 2009 Mar;98(3):861-93 [18683876.001]
  • [Cites] Lab Anim Sci. 1991 Jun;41(3):269-73 [1658469.001]
  • [Cites] Kobe J Med Sci. 2005;51(5-6):67-72 [16501317.001]
  • [Cites] Invasion Metastasis. 1994-1995;14(1-6):349-61 [7657528.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S52-5 [10357559.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):539-51 [15193257.001]
  • [Cites] Cancer Sci. 2006 May;97(5):355-61 [16630131.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):235-46 [10359143.001]
  • [Cites] Clin Exp Metastasis. 2009;26(4):329-44 [19190882.001]
  • [Cites] Clin Exp Metastasis. 2005;22(7):549-58 [16475025.001]
  • [Cites] Histol Histopathol. 2009 Jul;24(7):879-91 [19475534.001]
  • [Cites] Lab Anim. 1988 Jul;22(3):195-201 [3172698.001]
  • [Cites] Eur J Haematol. 2006 Aug;77(2):128-33 [16856908.001]
  • [Cites] Can J Neurol Sci. 2003 Nov;30(4):326-32 [14672264.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):337-42 [18661105.001]
  • [Cites] Lab Anim. 2004 Jul;38(3):286-96 [15207040.001]
  • [Cites] Mol Pharm. 2007 Jul-Aug;4(4):498-512 [17629304.001]
  • [Cites] Magn Reson Imaging. 2005 Nov;23(9):961-6 [16310112.001]
  • [Cites] Eur J Cancer. 1999 Aug;35(8):1286-91 [10615243.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2831-42 [12807936.001]
  • [Cites] ILAR J. 2002;43(4):191-3 [12391393.001]
  • [Cites] Nature. 2000 Aug 10;406(6796):641-5 [10949306.001]
  • [Cites] Contemp Top Lab Anim Sci. 2000 Jul;39(4):24-7 [11487225.001]
  • [Cites] Microcirculation. 2008 Jan;15(1):65-79 [17952797.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7023-32 [16203796.001]
  • [Cites] Ann N Y Acad Sci. 1999;889:45-51 [10668481.001]
  • [Cites] In Vivo. 1998 Jul-Aug;12(4):403-10 [9706492.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):359-62 [18678282.001]
  • [Cites] Anal Chim Acta. 2006 Feb 10;559(1):37-44 [16636700.001]
  • [Cites] Lab Anim Sci. 1999 Jun;49(3):319-23 [10403450.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):94-107 [18202697.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):175-84 [10389994.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4201-8 [17634549.001]
  • [Cites] Nature. 2010 Feb 18;463(7283):893-8 [20164919.001]
  • [Cites] J Laser Appl. 1993 Fall;5(2-3):43-60 [10146408.001]
  • [Cites] Biotechniques. 2002 Feb;32(2):432-4, 436, 438-40 [11848419.001]
  • [Cites] Exp Hematol. 2001 Mar;29(3):322-9 [11274760.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4572-83 [18628472.001]
  • [Cites] Br J Haematol. 1996 May;93(2):412-20 [8639441.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7 [11416159.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4239-43 [12874032.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):214-7 [16957739.001]
  • [Cites] Br J Cancer. 1993 Nov;68(5):909-15 [8217606.001]
  • [Cites] Curr Protoc Cytom. 2008 Jan;Appendix 3:Appendix 3C [18770641.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] J Microbiol. 2006 Feb;44(1):42-9 [16554716.001]
  • [Cites] Clin Cancer Res. 2010 Mar 1;16(5):1442-51 [20179238.001]
  • [Cites] J Vet Sci. 2001 Apr;2(1):53-8 [14614295.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1599-609 [9620848.001]
  • [Cites] Gut. 1999 Dec;45(6):812-7 [10562577.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):274-84 [19308067.001]
  • [Cites] Hum Cell. 2006 Feb;19(1):43-8 [16643607.001]
  • [Cites] Radiat Res. 2010 Jan;173(1):10-20 [20041755.001]
  • [Cites] J Chem Inf Model. 2006 May-Jun;46(3):1379-87 [16711757.001]
  • [Cites] Carcinogenesis. 2003 Dec;24(12):1887-96 [12949047.001]
  • [Cites] J Neurosci Methods. 2005 Oct 30;148(2):154-60 [15964078.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):836-9 [7531615.001]
  • [Cites] Anticancer Res. 2009 Nov;29(11):4389-95 [20032383.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):323-35 [18651209.001]
  • [Cites] Mol Imaging Biol. 2007 Mar-Apr;9(2):78-82 [17285239.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):2985-95 [9214616.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] World J Gastroenterol. 2007 Aug 14;13(30):4131-5 [17696236.001]
  • [Cites] Cancer Chemother Rep. 1966 May;50(4):219-44 [4957125.001]
  • [Cites] Gastroenterology. 2009 May;136(5):1514-25.e2 [19208341.001]
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):97-104 [16624384.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):513-6 [11212243.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1496-510 [16705038.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Toxicol Pathol. 2009 Feb;37(2):227-34 [19181629.001]
  • [Cites] Comb Chem High Throughput Screen. 2001 May;4(3):245-63 [11375740.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):1-4 [17960586.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):43-52 [12497205.001]
  • [Cites] J Natl Cancer Inst. 2006 May 3;98(9):580-98 [16670384.001]
  • [Cites] Science. 1997 Oct 3;278(5335):120-3 [9311916.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(1):45-56 [8738605.001]
  • [Cites] Lasers Med Sci. 2006 Dec;21(4):198-201 [16964439.001]
  • [Cites] Anticancer Drugs. 1999 Feb;10(2):229-33 [10211554.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5395-9 [1394144.001]
  • [Cites] Genes Dev. 2009 Apr 1;23(7):877-89 [19339691.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):27-43 [11259831.001]
  • [Cites] Lab Anim. 2006 Apr;40(2):111-4 [16600070.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8256-64 [19843858.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2995-3001 [10898343.001]
  • [Cites] Br J Anaesth. 2008 Jul;101(1):121-4 [18424804.001]
  • [Cites] Drug Metab Rev. 1997 Nov;29(4):891-922 [9421679.001]
  • [Cites] Cell Biol Toxicol. 2007 Nov;23(6):367-72 [17522957.001]
  • [Cites] J Drug Target. 2008 Aug;16(7):626-37 [18686134.001]
  • [Cites] Neoplasia. 1999 Apr;1(1):50-62 [10935470.001]
  • [Cites] Cell. 1987 May 22;49(4):465-75 [3032456.001]
  • [Cites] J Immunother. 2001 Nov-Dec;24(6):472-81 [11759070.001]
  • [Cites] Nat Biotechnol. 2005 Jul;23(7):790; author reply 791 [16003354.001]
  • [Cites] Mol Cancer Ther. 2010 Feb;9(2):257-67 [20124458.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S232-5 [8763887.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1055-62 [7692730.001]
  • [Cites] Endocrinology. 1968 May;82(5):1049-52 [5653116.001]
  • [Cites] Altern Lab Anim. 2005 Apr;33(2):119-27 [16180987.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):416-24 [11802201.001]
  • [Cites] J Am Assoc Lab Anim Sci. 2008 May;47(3):8-15 [18459706.001]
  • [Cites] World J Gastroenterol. 2005 Jun 14;11(22):3335-8 [15948235.001]
  • [Cites] Immunol Res. 2004;29(1-3):269-82 [15181288.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15608-13 [12438689.001]
  • [Cites] PLoS One. 2009;4(4):e4992 [19352430.001]
  • [Cites] Nat Genet. 1999 May;22(1):37-43 [10319859.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):796-806 [16195751.001]
  • [Cites] In Vivo. 2009 Sep-Oct;23(5):661-8 [19779098.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3351-4, discussion 3354 [16585151.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] Mol Cell. 1999 May;3(5):565-77 [10360173.001]
  • [Cites] Eur J Med Chem. 2008 Mar;43(3):501-12 [17574307.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1207-11 [10622530.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Aug;2(8):743-50 [19638489.001]
  • [Cites] Radiat Res. 1987 Dec;112(3):581-91 [3321144.001]
  • [Cites] J Epidemiol. 1999 Dec;9(6 Suppl):S58-65 [10709351.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7104s-7108s [16203809.001]
  • (PMID = 20502460.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10337; United Kingdom / Cancer Research UK / / 9993; United Kingdom / National Centre for the Replacement, Refinement and Reduction of Animals in Research / / G1000121/1; United Kingdom / Medical Research Council / / G0500366; United Kingdom / Cancer Research UK / / 10345
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Pharmacological
  • [Other-IDs] NLM/ PMC2883160
  •  go-up   go-down


57. Haase E, Yoo D, Sugarbaker PH: Management of appendiceal pseudomyxoma peritonei diagnosed during pregnancy. World J Surg Oncol; 2009;7:48
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of appendiceal pseudomyxoma peritonei diagnosed during pregnancy.
  • The most common types encountered during pregnancy are cervical, breast and ovarian.
  • Epithelial tumors of the appendix on the other hand are rare and account for only approximately 1% of all colorectal neoplasms; the occurrence of this neoplasm during pregnancy is extremely rare.
  • CASE PRESENTATION: The medical history of a 30 year old woman diagnosed at 17 weeks gestation with an appendiceal mucinous tumor with large volume pseudomyxoma peritonei was presented.
  • At 2 1/2 weeks postpartum the patient underwent extensive cytoreductive surgery and intraperitoneal chemotherapy.
  • She remains disease-free 5 years after her initial diagnosis.
  • A literature review of this clinical situation and a discussion of treatment plans were presented.
  • CONCLUSION: The management of an appendiceal tumor with pseudomyxoma peritonei diagnosed during pregnancy requires full knowledge of the natural history of this disease to achieve a balance of concern for maternal survival and fetal health.
  • [MeSH-major] Appendiceal Neoplasms / surgery. Peritoneal Neoplasms / surgery. Pregnancy Complications, Neoplastic / surgery. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):304-11 [14991630.001]
  • [Cites] Am J Perinatol. 2001 May;18(3):155-7 [11414527.001]
  • [Cites] J Obstet Gynaecol. 2003 Sep;23(5):566-7 [12963525.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):585-603 [14567019.001]
  • [Cites] J Reprod Med. 2003 Oct;48(10):831-3 [14619655.001]
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):93-6 [17262739.001]
  • [Cites] J Reprod Med. 2004 Sep;49(9):753-5 [15493568.001]
  • [Cites] CA Cancer J Clin. 1983 Jul-Aug;33(4):194-214 [6407725.001]
  • [Cites] Am J Obstet Gynecol. 1986 Mar;154(3):637-8 [3953713.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jan;271(1):86-8 [15316825.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • [Cites] J R Soc Med. 2000 Apr;93(4):192-3 [10844886.001]
  • (PMID = 19454019.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC2688488
  •  go-up   go-down


58. Chen HT, Lee YT, Chou AS, Wu YK, Yin WY, Lee MC, Hsu YH: Primary appendiceal malignancy: a clinicopathologic study. Kaohsiung J Med Sci; 2006 Dec;22(12):618-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary appendiceal malignancy: a clinicopathologic study.
  • Primary appendiceal cancer is a rare neoplasm.
  • We analyzed the clinicopathologic characteristics and clinical outcomes of patients with primary appendiceal cancer treated at Buddhist Tzu Chi General Hospital in Eastern Taiwan.
  • We reviewed the medical records of patients who had appendectomy at our hospital over a 10-year period and studied those who had histologically proven malignant appendiceal neoplasms.
  • There were three mucinous adenocarcinomas, two colonic type adenocarcinomas, and three adenocarcinoids.
  • No patient was diagnosed correctly before surgery, and five (62.5%) had a preoperative diagnosis of acute appendicitis.
  • The important prognostic factors of primary appendiceal cancer included histologic subtypes and the extent of dissemination.
  • In our series, palliative resection for disseminated lesions with or without additional chemotherapy resulted in long-term survival.
  • [MeSH-major] Appendiceal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Aged. Cystadenocarcinoma, Mucinous / pathology. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116623.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


59. Miquel C, Sabourin JC, Elias D, Grandjouan S, Viguier J, Ducreux M, Duvillard P, Praz F: An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer. Hum Pathol; 2004 Dec;35(12):1564-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer.
  • Gastrointestinal carcinoid tumors are often associated with other tumors, particularly colon adenocarcinomas; but the association between carcinoid tumors and hereditary nonpolyposis colorectal cancer (HNPCC) syndrome has not yet been explored.
  • We report an unusual case of a 28-year-old woman with HNPCC who underwent surgery for a transverse colon adenocarcinoma in whom an appendix carcinoid tumor was incidentally found.
  • To assess whether the carcinoid tumor displayed the characteristic molecular features of HNPCC tumors, we investigated the expression of mismatch-repair (MMR) proteins and microsatellite instability (MSI) status in both tumors.
  • Both tumors demonstrated normal expression of the MMR proteins hMLH1, hMSH2, hMSH6, and hPMS2.
  • Interestingly, the adenocarcinoma exhibited an MSI phenotype but the carcinoid tumor did not, indicating that these 2 tumors arose through different molecular pathways.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Carcinoid Tumor / pathology. Colonic Neoplasms / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. DNA-Binding Proteins / analysis. Drug Therapy, Combination. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Microsatellite Repeats / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15619218.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MSH3 protein, human; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


60. Seager C, Puzio-Kuter AM, Cordon-Cardo C, McKiernan J, Abate-Shen C: Mouse models of human bladder cancer as a tool for drug discovery. Curr Protoc Pharmacol; 2010 Jun;Chapter 14:Unit14.14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse models of human bladder cancer as a tool for drug discovery.
  • Muscle-invasive bladder cancer is a deadly condition in dire need of effective new treatments.
  • This unit contains a description of mouse models suitable for the evaluation of potential new therapies.
  • Also described is an orthotopic mouse model created by the instillation of human bladder tumor cells into the bladder lumen of immune deficient mice.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Cell. 2004 Jan;6(1):7-28 [14723844.001]
  • [Cites] Cancer Gene Ther. 2000 Dec;7(12):1575-80 [11228536.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):952-9 [14737125.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):111-6 [15324694.001]
  • [Cites] Cancer Res. 1987 Dec 15;47(24 Pt 1):6660-5 [3677100.001]
  • [Cites] J Urol. 1991 Jun;145(6):1297-301 [2033720.001]
  • [Cites] Lancet. 1993 Aug 21;342(8869):469-71 [8102431.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):394-8 [16481738.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5277-87 [17000660.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5288-97 [17000661.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5312-28 [17000664.001]
  • [Cites] BJU Int. 2007 Dec;100(6):1377-84 [17850390.001]
  • [Cites] Curr Protoc Mol Biol. 2006 May;Appendix 3:Appendix 3F [18265370.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2132-44 [18381418.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3051-64 [18725989.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):116-30 [18815926.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65 [18815930.001]
  • [Cites] Genes Dev. 2009 Mar 15;23(6):675-80 [19261747.001]
  • [Cites] Annu Rev Pathol. 2009;4:251-85 [18840072.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Dec;2(12):1008-14 [19952358.001]
  • [Cites] Genesis. 2002 Feb;32(2):148-9 [11857804.001]
  • (PMID = 22294368.001).
  • [ISSN] 1934-8290
  • [Journal-full-title] Current protocols in pharmacology
  • [ISO-abbreviation] Curr Protoc Pharmacol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA091846; United States / NCI NIH HHS / CA / U01 CA084294; United States / NCI NIH HHS / CA / P50 CA91846; United States / NCI NIH HHS / CA / P50 CA091846-03; United States / NCI NIH HHS / CA / U01 CA084294-11; None / None / / P50 CA091846-03; United States / NCI NIH HHS / CA / CA084294-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS211813; NLM/ PMC3272628
  •  go-up   go-down


61. Lugo JZ, Avgerinos DV, Lefkowitz AJ, Seigerman ME, Zahir IS, Lo AY, Surick B, Leitman IM: Can interval appendectomy be justified following conservative treatment of perforated acute appendicitis? J Surg Res; 2010 Nov;164(1):91-4
MedlinePlus Health Information. consumer health - Appendicitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can interval appendectomy be justified following conservative treatment of perforated acute appendicitis?
  • While recent studies suggest that the risk of recurrent disease is small, the risk of interval appendectomy is also small and does provide histologic identification and usually definitive treatment of the right lower quadrant inflammatory process.
  • Ninety-four percent of the appendectomies were completed laparoscopically; 16% of patients were found to have a normal or obliterated appendix on pathologic evaluation and likely did not benefit from interval appendectomy.
  • On the other hand, 84% of patients had persistent acute appendicitis, chronic appendicitis, evidence of inflammatory bowel disease, or neoplasm identified, and likely benefited from surgical appendectomy.
  • CONCLUSIONS: Interval appendectomy provides diagnostic and therapeutic benefit to patients who present with a right lower quadrant abdominal inflammatory focus, and should be carefully considered in all adult patients.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Appendectomy. Appendicitis / drug therapy. Appendicitis / surgery. Unnecessary Procedures
  • [MeSH-minor] Abdominal Abscess / drug therapy. Abdominal Abscess / epidemiology. Abdominal Abscess / surgery. Acute Disease. Adult. Cellulitis / drug therapy. Cellulitis / epidemiology. Cellulitis / surgery. Female. Humans. Infusions, Intravenous. Male. Recurrence. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19691990.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


62. Spunt SL, Pratt CB, Rao BN, Pritchard M, Jenkins JJ, Hill DA, Cain AM, Pappo AS: Childhood carcinoid tumors: the St Jude Children's Research Hospital experience. J Pediatr Surg; 2000 Sep;35(9):1282-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood carcinoid tumors: the St Jude Children's Research Hospital experience.
  • BACKGROUND/PURPOSE: To better characterize childhood carcinoid tumors, the authors reviewed the clinical presentation, treatment, and outcomes of pediatric patients with these rare tumors.
  • METHODS: A retrospective review was conducted of medical records and pathologic materials of all children with carcinoid tumors treated at St Jude Children's Research Hospital between December 1977 and March 1999.
  • Primary tumor sites were the appendix (n = 5), small intestine (n = 1), bronchus (n = 1), and 1 unknown site.
  • In 7 cases, carcinoid tumor was not suspected at the time the tumor was identified.
  • Seven patients had localized disease; 5 remain disease-free after complete resection, and 2, whose carcinoid tumors were identified incidentally, died of metastatic mucinous adenocarcinoma of the colon.
  • One patient who presented with symptoms of carcinoid syndrome had metastatic disease that responded poorly to cytotoxic chemotherapy and remains alive with active disease.
  • CONCLUSIONS: Although most pediatric carcinoid tumors arise in the appendix, these tumors also occur in other primary sites.
  • Clinical awareness and early diagnosis are important factors in preventing morbidity and mortality.
  • Outcomes are excellent for patients with localized disease that is completely resected, but those with metastatic disease fare poorly.
  • New therapeutic strategies are needed for these patients.
  • [MeSH-major] Appendiceal Neoplasms. Bronchial Neoplasms. Carcinoid Tumor. Intestinal Neoplasms
  • [MeSH-minor] Adolescent. Appendectomy. Child. Female. Humans. Male. Pneumonectomy. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10999679.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 23099; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


63. Kornovski Ia, Ianeva R, Kornovski D: [Retroperitoneal approach and pelvic peritoneoectomy in the surgical management of advanced ovarian cancer]. Akush Ginekol (Sofiia); 2006;45(6):61-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To share our experience in surgical management of advanced ovarian cancer applying a retroperitoneal approach and performing pelvic peritoneoectomy for the achievement of an optimal debulking in this disease.
  • Thirty patients presented without previous therapy, 3 - after total abdominal hysterectomy with adnexes, 1 - after supravaginal hysterectomy with adnexes, 1 - after unilateral adnexectomy and 3 - after neoadjuvant chemotherapy.
  • RESULTS: Maximal (no evidence of disease) and optimal (less than 2 cm lesion) cytoreduction is achieved in 23 (60,5%) and 8 (21,1%) patients, respectively - totally in 81,6% of all patients.
  • The most common site of suboptimal (> 2 cm) residual masses is the anterior rectal wall and cavum Douglasi - 85,7%, Lymph node metastases is detected in 33%, metastases in omentum - in 75%, parametrial invasion - in 25%, vaginal metastases - in 8,3%, metastases in appendix and Fallopian tubes - in 47,8% and 8,8%, respectively and invasion of tumor's capsula - in 34, 2%.
  • [MeSH-major] Gynecologic Surgical Procedures / methods. Ovarian Neoplasms / surgery. Peritoneum / surgery. Retroperitoneal Space / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168488.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


64. Murphy EM, Sexton R, Moran BJ: Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum; 2007 Jan;50(1):37-42
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm.
  • PURPOSE: Epithelial appendiceal tumors are uncommon but can present as an emergency simulating appendicitis, or unexpectedly at laparotomy, laparoscopy, or on cross-sectional imaging.
  • We report the operative findings, pathologic assessment, and early outcomes in 123 consecutive patients with a perforated appendiceal neoplasm presenting as pseudomyxoma peritonei.
  • METHODS: From March 1994 to March 2004, 292 patients were referred to a peritoneal malignancy surgical treatment center.
  • Complete tumor removal (cytoreduction) was attempted in selected patients and, if achieved, surgery was combined with intraoperative, intraperitoneal mitomycin C (10 mg/m(2)).
  • RESULTS: In total, 123 patients (52 males; 41 percent) underwent laparotomy for a perforated appendiceal malignancy presenting as pseudomyxoma peritonei.
  • Kaplan-Meier analysis of the 83 patients who had complete tumor removal predicted 75 percent disease-free survival at five years.
  • CONCLUSIONS: A perforated appendiceal epithelial tumor most frequently presents as pseudomyxoma peritonei.
  • This treatment strategy, involving surgery and intraperitoneal chemotherapy, can result in good outcomes in this rare and otherwise fatal disease.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Postoperative Complications. Rupture

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2007 Sep;4(9):490-1 [17667901.001]
  • (PMID = 17115339.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


65. Li C, Kanthan R, Kanthan SC: Pseudomyxoma peritonei--a revisit: report of 2 cases and literature review. World J Surg Oncol; 2006;4:60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare, chronic, relapsing, diagnostically challenging and poorly understood disease characterized by disseminated mucinous ascites and peritoneal implants.
  • CASE PRESENTATION: We report two cases of PMP that represent the two biological variants of disseminated peritoneal adenomucinosis (DPAM)--the benign variant and the peritoneal mucinous carcinomatosis (PMCA)--the malignant variant, both of which were characterized by multiple relapses and progression of the disease despite aggressive management.
  • CONCLUSION: Even with a better understanding and recent advances in the management of these cases, PMP remains an enigmatic disease with a protracted clinical course characterized by multiple recurrences despite surgery and/or chemotherapy.
  • Recognition of PMP as a delayed consequence years later should alert all surgeons to be extremely vigilant when treating mucinous neoplasms of the appendix, with special care being directed towards adequate excision and thorough debridement at the initial diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2005 Nov;12(6):291-311 [16330927.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(2):73-80 [11223697.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):551-64 [12163380.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):571-8 [12717243.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):1-9 [8986525.001]
  • [Cites] Cancer Treat Res. 1996;81:121-32 [8834580.001]
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):441-7 [8211593.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] J Am Coll Surg. 2006 Apr;202(4):680-4 [16571440.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1849-55 [10362811.001]
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):186-90 [16303281.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):382-6 [15932563.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] J Surg Oncol. 2004 Sep 15;87(4):162-6 [15334630.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(4):411-4 [15285293.001]
  • [Cites] World J Surg Oncol. 2004;2:19 [15180896.001]
  • (PMID = 16945158.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1574320
  •  go-up   go-down


66. Lepistö A, Osterlund P, Järvinen HJ: [Treatment of pseudomyxoma peritonei is developing]. Duodecim; 2010;126(14):1693-9
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pseudomyxoma peritonei is developing].
  • In pseudomyxoma peritonei a mucinous tumor of the appendix spreads into the abdominal cavity.
  • Cytologic picture of the tumor may be benign, malignant or intermediary.
  • The symptoms were previously relieved by repeated resections of the tumor mass, whereby even the most benign form of the disease progressed slowly.
  • This treatment is associated with a morbidity of 33 to 56% and a mortality of 0 to 18%.
  • Controlled studies have not been carried out on the novel treatment.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Appendix / pathology. Combined Modality Therapy. Disease Progression. Humans. Neoplasm Invasiveness. Therapeutic Irrigation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804088.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Finland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down






Advertisement